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Abstract
High blood pressure is a highly heritable and modifiable risk factor for cardiovascular disease. We 
report the largest genetic association study of blood pressure traits (systolic, diastolic, pulse 
pressure) to date in over one million people of European ancestry. We identify 535 novel blood 
pressure loci that not only offer new biological insights into blood pressure regulation but also 
reveal shared genetic architecture between blood pressure and lifestyle exposures. Our findings 
identify new biological pathways for blood pressure regulation with potential for improved 
cardiovascular disease prevention in the future.
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Introduction
High blood pressure (BP) is a leading heritable risk factor for stroke and coronary artery 
disease, responsible for an estimated 7.8 million deaths and 148 million disability life years 
lost worldwide in 2015 alone1. Blood pressure is determined by complex interactions 
between life-course exposures and genetic background2–4. Previous genetic association 
studies have identified and validated variants at 274 loci with modest effects on population 
BP, explaining in aggregate ~3% of the trait variance5–12.
Here, we report genome-wide discovery analyses of BP traits - systolic (SBP), diastolic 
(DBP) and pulse pressure (PP) - in people of European ancestry drawn from UK Biobank 
(UKB)13 and the International Consortium of Blood Pressure-Genome Wide Association 
Studies (ICBP)11,12. We adopted a combination of a one- and two-stage study design to test 
common and low-frequency single nucleotide polymorphisms (SNPs) with minor allele 
frequency (MAF) ≥ 1% associated with BP traits (Fig. 1). In all, we studied over 1 million 
people of European descent, including replication data from the US Million Veterans 
Program (MVP, N=220,520)14 and the Estonian Genome Centre, University of Tartu 
(EGCUT, N=28,742) Biobank15.
UKB is a prospective cohort study of ~500,000 richly phenotyped individuals, including BP 
measurements13, with genotyping by customized array and imputation from the Haplotype 
Reference Consortium (HRC) panel, yielding ~7 million SNPs (imputation quality score 
(INFO) ≥ 0.1 and MAF ≥ 1%)16. We performed genome-wide association studies (GWAS) 
of BP traits (N=458,577 Europeans) under an additive genetic model17 (Supplementary 
Table 1a). Following LD-score regression18, genomic control (GC) was applied to the UKB 
data prior to meta-analysis (Online methods).
In addition, we performed GWAS analyses for BP traits in newly extended ICBP GWAS 
data comprising 77 independent studies for up to 299,024 Europeans genotyped with various 
arrays, and imputed to either the 1,000 Genomes Reference Panel or the HRC platforms 
(Supplementary Table 1b). After QC we applied GC at the individual study level and 
obtained summary effect sizes for ~7 million SNPs with INFO ≥ 0.3 and heterogeneity 
Cochran’s Q statistic19 filtered at P ≥ 1 × 10-4 (Online Methods).
We then combined the UKB and ICBP GWAS results using inverse-variance weighted fixed 
effects meta-analysis (Online Methods), giving a total discovery sample of up to 757,601 
individuals20.
In our two-stage design we attempted replication (in MVP and EGCUT, Supplementary 
Table 1c) of 1,062 SNPs at P < 1 × 10-6 from discovery with concordant effect direction 
between UKB and ICBP, using the sentinel SNP (i.e. SNP with smallest P-value at the locus) 
after excluding the HLA region (chr 6:25-34MB) and all SNPs in Linkage Disequilibrium 
(LD) (r2 ≥ 0.1) or ±500 Kb from any previously validated BP-associated SNPs at the 274 
published loci. Our replication criteria were genome-wide significance (P < 5 × 10-8) in the 
combined meta-analysis, P < 0.01 in the replication data and concordant direction of effect 
between discovery and replication.
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We additionally undertook a one-stage design to reduce type II error from the two-stage 
analysis. We used P < 5 × 10-9 as threshold from the discovery meta-analysis, i.e. an order of 
magnitude more stringent than genome-wide significance21, and required an internal 
replication P < 0.01 in each of the UKB and ICBP GWAS analyses, with concordant 
direction of effect, to minimize false positive findings.
We carried out conditional analyses using genome-wide complex trait analysis (GCTA)22. 
We then explored putative function of BP-associated signals using a range of in silico 
resources, and evaluated co-occurrence of BP-associated loci with lifestyle exposures and 
other complex traits and diseases. Finally, we developed a genetic risk score (GRS) and 
assessed impact of BP-associated variants on BP level, risk of hypertension (HTN), other 
cardiovascular diseases and in other ethnicities.
Results
We present a total of 535 novel loci (Fig.2, Supplementary Fig. 1): 325 loci claimed from the 
two-stage design (Supplementary Tables 2a-c) and an additional 210 claimed from our one-
stage design with internal replication (Supplementary Tables 3a-c). Our two-stage design 
uniquely identified 121 variants, while 204 also met the one-stage criteria (Fig. 3a); large 
numbers of loci would not have been detected by either the one- or two-stage designs alone 
(Fig. 3a). For SBP, the distributions of effect sizes are similar for the one-stage (median = 
0.219 mmHg per allele; Inter-Quartile Range (IQR) = 0.202-0.278) and two-stage loci 
(median = 0.224; IQR = 0.195-0.267) (P = 0.447) (Supplementary Fig. 2). Of the 210 loci 
found only in the one-stage analysis, 186 are also genome-wide significant (P < 5 × 10-8) in 
the combined meta-analysis, with all variants, except one, having concordant direction of 
effect between discovery and replication (Supplementary Tables 3a-c); of the remaining 24 
SNPs, 10 still have concordant direction of effect.
We find support in our data for all 274 previously published BP loci (Supplementary Fig. 1 
& 2 and Supplementary Table 4); >95% of the previously reported SNPs covered within our 
data are genome-wide significant. Only 6 available SNPs did not reach Bonferroni-
significance, likely because they were originally identified in non-European ancestries (e.g. 
rs6749447, rs10474346, rs11564022), or from a gene-age interaction analysis (rs16833934). 
In addition, we confirmed a further 92 previously reported, but not replicated, loci 
(Supplementary Table 5)9; together with 274 previously reported loci confirmed, and 535 
novel loci identified here, there are 901 BP-associated loci in total.
Novel genetic loci for blood pressure
Of the 535 independent novel loci, 363 SNPs were associated with one trait, 160 with two 
traits and 12 with all three BP traits (Fig. 3b, Supplementary Fig. 3). Using GCTA we 
additionally identified 163, genome-wide significant, independent secondary signals with 
MAF ≥ 1% associated with BP (Supplementary Table 6), of which 19 SNPs are in LD (r2 ≥ 
0.1) with previously reported secondary signals. This gives a total of 144 new secondary 
signals; hence we now report over 1,000 independent BP signals.
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The estimated SNP-wide heritability (h2) of BP traits in our data was 0.213, 0.212 and 0.194 
for SBP, DBP and PP respectively, with a gain in percentage of BP variance explained. For 
example, for SBP, percentage variance explained increased from 2.8 % for the 274 
previously published loci to 5.7% for SNPs identified at all 901 loci (Supplementary Table 
7).
Functional analyses
Our functional analyses approach is summarised in Supplementary Figure 4. First, for each 
of the 901 loci we annotated all SNPs (based on LD r2 ≥ 0.8) to the nearest gene within 5kb 
of a SNP, identifying 1333 genes for novel loci and 1272 genes for known loci. Then we 
investigated these loci for tissue enrichment, DNase hypersensitivity site enrichment and 
pathway analyses. At 66 of the 535 novel loci we identified 97 non-synonymous SNPs, 
including 8 predicted to be damaging (Supplementary Table 8).
We used chromatin interaction Hi-C data from endothelial cells (HUVEC)23, neural 
progenitor cells (NPC), mesenchymal stem cells (HVMSC) and tissue from the aorta 
(HAEC) and adrenal gland24 to identify distal associated genes. There were 498 novel loci 
that contained a potential regulatory SNP and in 484 of these we identified long-range 
interactions in at least one of the tissues or cell types. We found several potential long-range 
target genes that do not overlap with the sentinel SNPs in the LD block. For example, the 
TGFB2 gene forms a 1.2Mb regulatory loop with SNPs in the SLC30A10 locus, and the 
TGFBR1 promoter forms a 100kb loop with the COL15A1 locus (Supplementary Table 8).
Our eQTL analysis identified 60 novel loci with eQTLs in arterial and 20 in adrenal tissue 
(Supplementary Table 9), substantially increasing those identified in our previously 
published GWAS on ~140K UKB individuals10. An example is SNP rs31120122 which 
defines an aortic eQTL affecting expression of the MED8 gene within the SZT2 locus. In 
combination with Hi-C interaction data in MSC, this supports a role for MED8 in BP 
regulation, possibly mediated through repression of smooth muscle cell differentiation. Hi-C 
interactions provide supportive evidence for involvement of a further 36 arterial eGenes 
(genes whose expression is affected by the eQTLs) that were distal to their eQTLs (e.g 
PPHLN1, ERAP2, FLRT2, ACVR2A, POU4F1).
Using DeepSEA we found 198 SNPs in 121 novel loci with predicted effects on 
transcription factor binding or on chromatin marks in tissues relevant for BP biology, such as 
vascular tissue, smooth muscle and the kidney (Supplementary Table 8).
We used our genome-wide data at a false discovery rate (FDR) < 1% to robustly assess 
tissue enrichment of BP loci using DEPICT and identified enrichment across 50 tissues and 
cells. (Supplementary Fig 5a; Supplementary Table 10a). Enrichment was greatest for the 
cardiovascular system especially blood vessels (P = 1.5 × 10-11) and the heart (P = 2.7 × 
10-5). Enrichment was high in adrenal tissue (P = 3.7 × 10-4) and, for the first time, we 
observed high enrichment in adipose tissues (P = 9.8 × 10-9) corroborated by eQTL 
enrichment analysis (P < 0.05) (Supplementary Fig. 6; Supplementary Table 9). Evaluation 
of enriched mouse knockout phenotype terms also points to the importance of vascular 
morphology (P = 6 × 10-15) and development (P = 2.1 × 10-18) in BP. With addition of our 
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novel BP loci, we identified new findings from both the gene ontology and protein-protein 
interaction subnetwork enrichments, which highlight the TGFβ (P = 2.3 × 10-13) and related 
SMAD pathways (P = 7 × 10-15) (Supplementary Table 10b, Supplementary Fig. 5b-d).
We used FORGE25 to investigate the regulatory regions for cell type specificity from DNase 
I hypersensitivity sites, which showed strongest enrichment (P < 0.001) in the vasculature 
and highly vascularised tissues, as reported in previous BP genetic studies10 
(Supplementary Fig. 7).
Potential therapeutic targets
Ingenuity pathway analysis and upstream regulator assessment showed enrichment of 
canonical pathways implicated in cardiovascular disease including pathways targeted by 
antihypertensive drugs (e.g. nitric oxide signalling) and also suggested some potential new 
targets, such as relaxin signalling. Notably, upstream regulator analysis identified several BP 
therapeutic targets such as angiotensinogen, calcium channels, progesterone, natriuretic 
peptide receptor, angiotensin converting enzyme, angiotensin receptors and endothelin 
receptors (Supplementary Fig. 8).
We developed a cumulative tally of functional evidence at each variant to assist in variant/
gene prioritisation at each locus and present a summary of the vascular expressed genes 
contained within the 535 novel loci, including a review of their potential druggability 
(Supplementary Fig. 9). The overlap between BP-associated genes and those associated with 
antihypertensive drug targets further demonstrates new genetic support for known drug 
mechanisms. For example, we report five novel BP associations with targets of five 
antihypertensive drug classes (Supplementary Table 11), including the PKD2L1, SLC12A2, 
CACNA1C, CACNB4 and CA7 loci - targeted by potassium-sparing diuretics (amiloride), 
loop diuretics (bumetanide and furosemide), dihydropyridine, calcium channel blockers, 
non-dihydropyridines and thiazide-like diuretics (chlortalidone) respectively. Notably in all 
but the last case, functional variants in these genes are the best candidates in each locus.
Concordance of BP variants and lifestyle exposures
We examined association of sentinel SNPs at the 901 BP loci with BP-associated lifestyle 
traits14 in UKB using either the Stanford Global Biobank Engine (N=327,302) or Gene 
ATLAS (N=408,455). With corrected P < 1 × 10-6, we found genetic associations of BP 
variants with daily fruit intake, urinary sodium and creatinine concentration, body mass 
index (BMI), weight, waist circumference, and intakes of water, caffeine and tea (P = 1.0 × 
10-7 to P = 1.3 × 10-46). Specifically, SNP rs13107325 in SLC39A8 is a novel locus for 
frequency of drinking alcohol (P = 3.5 × 10-15) and time spent watching TV (P = 2.3 × 
10-11) as well as being associated with BMI (P = 1.6 × 10-33), weight (P = 8.8 × 10-16) and 
waist circumference (P = 4.7 × 10-11) (Supplementary Table 12). We used unsupervised 
hierarchical clustering for the 36 BP loci that showed at least one association at P < 1 × 10-6 
with the lifestyle-related traits in UKB (Fig. 4). The heatmap summarises the locus-specific 
associations across traits and highlights heterogeneous effects with anthropometric traits 
across the loci examined. For example, it shows clusters of associations between BP-raising 
alleles and either increased or decreased adult height and weight. We note that some 
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observed cross-trait associations are in counter-directions to those expected 
epidemiologically.
Association lookups with other traits and diseases
We further evaluated cross-trait and disease associations using GWAS catalog26, 
PhenoScanner27 and DisGeNET28,29. The GWAS catalog and PhenoScanner search of 
published GWAS showed that 77 of our 535 novel loci (using sentinel SNPs or proxies; r2 ≥ 
0.8) are also significantly associated with other traits and diseases (Fig. 5, Supplementary 
Table 13). We identified APOE as a highly cross-related BP locus showing associations with 
lipid levels, cardiovascular-related outcomes and Alzheimer’s disease, highlighting a 
common link between cardiovascular risk and cognitive decline (Fig. 5). Other loci overlap 
with anthropometric traits, including BMI, birth weight and height (Fig. 5) and with 
DisGeNET terms related to lipid measurements, cardiovascular outcomes and obesity (Fig. 
6).
We did lookups of our sentinel SNPs in 1H NMR lipidomics data on plasma (N=2,022) and 
data from the Metabolon platform (N=1,941) in the Airwave Study30, and used 
PhenoScanner to test SNPs against published significant (P < 5 × 10-8) genome vs 
metabolome-wide associations in plasma and urine (Online Methods). Ten BP SNPs show 
association with lipid particle metabolites and a further 31 SNPs (8 also on PhenoScanner) 
show association with metabolites on the Metabolon platform, highlighting lipid pathways, 
amino acids (glycine, serine, glutamine), tri-carboxylic acid cycle intermediates 
(succinylcarnitine) and drug metabolites (Supplementary Tables 14 and 15). These findings 
suggest a close metabolic coupling of BP regulation with lipid and energy metabolism.
Genetic risk of increased blood pressure, hypertension and cardiovascular disease
A weighted GRS for BP levels across all 901 loci was associated with a 10.4 mmHg higher, 
sex-adjusted mean SBP in UK Biobank comparing the upper and lower quintiles of the GRS 
distribution (95% CI: 10.2 to 10.6 mm Hg, P < 1 × 10-300) and with 12.9 mmHg difference 
in SBP (95% CI: 12.6 to 13.1, P < 1 × 10-300) comparing the upper and lower deciles (Fig. 
7a, Supplementary Table 16). In addition, we observed over three-fold sex-adjusted higher 
risk of hypertension (OR 3.34; 95% CI: 3.24 to 3.45; P < 1 × 10-300) between the upper and 
lower deciles of the GRS in UK Biobank (Fig. 7a). Sensitivity analyses in the independent 
Airwave cohort gave similar results (Supplementary Table 17).
We also show that the GRS is associated with increased, sex-adjusted risk of incident stroke, 
myocardial infarction and all incident cardiovascular outcomes, comparing upper and lower 
deciles of the GRS distribution, with odds ratios of 1.47 (95% CI: 1.35 to 1.59, P = 1.1 × 
10-20), 1.50 (95% CI: 1.28 to 1.76, P = 8.0 × 10-7) and 1.52 (95% CI: 1.26 to 1.82, P = 7.7 × 
10-6) respectively (Fig. 7b, Supplementary Table 16).
Extending analyses to other ancestries
We examined associations with BP of both individual SNPs and the GRS among unrelated 
individuals of African and South Asian descent in UKB, for the 901 known and novel loci. 
Compared to Europeans, 62.4%, 62.5% and 64.8% of the variants among Africans 
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(N=7,782), and 74.2%, 72.3% and 75% South Asians (N=10,323) have concordant direction 
of effect for SBP, DBP and PP respectively (Supplementary Table 18; Supplementary Fig. 
10). Pearson correlation coefficients with effect estimates in Europeans were r2= 0.37 and 
0.78 for Africans and South Asians respectively (Supplementary Fig. 11). We then applied 
the European-derived GRS findings to unrelated Africans (N=6,970) and South Asians 
(N=8,827). BP variants in combination were associated with 6.1 mmHg (95% CI: 4.5 to 7.7; 
P = 4.9 × 10-14) and 7.4 mmHg (95% CI: 6.0 to 8.7; P = 1.7 × 10-26) higher, sex-adjusted 
mean systolic pressure among Africans and South Asians, respectively, comparing upper and 
lower quintiles of the GRS distribution (Supplementary Tables 19a and 19b).
Discussion
Our study of over 1 million people offers an important step forward in understanding the 
genetic architecture of BP. We identified over 1,000 independent signals at 901 loci for BP 
traits, and the 535 novel loci more than triples the number of BP loci and doubles the 
percentage variance explained, illustrating the benefits of large-scale biobanks. By 
explaining 27% of the estimated heritability for BP, we make major inroads into the missing 
heritability influencing BP level in the population31. The novel loci open the vista of 
entirely new biology and highlight gene regions in systems not previously implicated in BP 
regulation. This is particularly timely as global prevalence of people with SBP over 110-115 
mm Hg, above which cardiovascular risk increases in a continuous graded manner, now 
exceeds 3.5 billion, of whom over 1 billion are within the treatment range 32,33.
Our functional analysis highlights the role of the vasculature and associated pathways in the 
genetics underpinning BP traits. We show a role for several loci in the transforming growth 
factor beta (TGFβ) pathway including SMAD family genes and the TGFβ gene locus itself. 
This pathway affects sodium handling in the kidney, ventricular remodelling, while plasma 
levels of TGFβ have recently been correlated with hypertension (Fig. 8)34,35. The activin A 
receptor type 1C (ACVR1C) gene mediates the effects of the TGFβ family of signalling 
molecules. A BP locus contains the Bone Morphogenetic Protein 2 (BMP2) gene in the 
TGFβ pathway, which prevents growth suppression in pulmonary arterial smooth muscle 
cells and is associated with pulmonary hypertension36. Another BP locus includes the 
Kruppel-like family 14 (KLF14) gene of transcription factors, induced by low levels of 
TGFβ receptor II gene expression, and which has also been associated with type 2 diabetes, 
hypercholesterolaemia and atherosclerosis37.
Our analysis shows enrichment of BP gene expression in the adrenal tissue. Autonomous 
aldosterone production by the adrenal glands is thought to be responsible for 5-10% of all 
hypertension, rising to ,20% amongst people with resistant hypertension38. Some of our 
novel loci are linked functionally to aldosterone secretion39,40. For example, the CTNNB1 
locus encodes β-catenin, the central molecule in the canonical Wnt signalling system, 
required for normal adrenocortical development41,42. Somatic adrenal mutations of this 
gene that prevent serine/threonine phosphorylation lead to hypertension through generation 
of aldosterone-producing adenomas43,44.
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Our novel loci also include genes involved in vascular remodelling, such as vascular 
endothelial growth factor A (VEGFA), the gene product of which induces proliferation, 
migration of vascular endothelial cells and stimulates angiogenesis. Disruption of this gene 
in mice resulted in abnormal embryonic blood vessel formation, while allelic variants of this 
gene have been associated with microvascular complications of diabetes, atherosclerosis and 
the antihypertensive response to enalapril45. We previously reported a fibroblast growth 
factor (FGF5) gene locus in association with BP10. Here, we additionally identify a new BP 
locus encoding FGF9, which is linked to enhanced angiogenesis and vascular smooth 
muscle cell differentiation by regulating VEGFA expression.
Several of our novel loci contain lipid-related genes consistent with the observed strong 
associations among multiple cardio-metabolic traits. For example, the apolipoprotein E gene 
(APOE) encodes the major apoprotein of the chylomicron. Recently, APOE serum levels 
have been correlated with SBP in population-based studies and in murine knockout models; 
disruption of this gene led to atherosclerosis and hypertension46,47. A second novel BP 
locus contains the low-density lipoprotein receptor-related protein 4 (LRP4) gene which may 
be a target for APOE and is strongly expressed in the heart in mice and humans. In addition, 
we identified a novel locus including the apolipoprotein L domain containing 1 gene 
(APOLD1) that is highly expressed in the endothelium of developing tissues (particularly 
heart) during angiogenesis.
Many of our novel BP loci encode proteins which may modulate vascular tone or signalling. 
For example, the locus containing urotensin-2 receptor (UTS2R) gene encodes a class A 
rhodopsin family G-protein coupled-receptor that upon activation by the neuropeptide 
urotensin II, produces profound vasoconstriction. One novel locus for SBP contains the 
relaxin gene, encoding a G-protein coupled receptor, with roles in vasorelaxation and 
cardiac function; it signals by phosphatidylinositol 3-kinase (PI3K)48,49, an enzyme which 
inhibits vascular smooth muscle cell proliferation and neo-intimal formation50. We identify 
the PI3K gene here as a novel BP locus. We also identify the novel RAMP2 locus which 
encodes an adrenomedullin receptor51; we previously identified the adrenomedullin (ADM) 
gene as a BP locus12. Adrenomedullin is known to exert differential effects on BP in the 
brain (vasopressor) and the vasculature (vasodilator). In addition, a locus containing Rho 
guanine nucleotide exchange factor 25 (ARHGEF25) gene generates a factor that interacts 
with Rho GTPases involved in contraction of vascular smooth muscle and regulation of 
responses to angiotensin II52.
We evaluated the 901 BP loci for extant or potentially druggable targets. Loci encoding 
MARK3, PDGFC, TRHR, ADORA1, GABRA2, VEGFA and PDE3A are within systems 
with existing drugs not currently linked to a known antihypertensive mechanism; they may 
offer repurposing opportunities e.g. detection of SLC5A1 as the strongest repurposing 
candidate in a new BP locus targeted by the type-2 diabetes drug canagliflozin. This is 
important as between 8-12% of patients with hypertension exhibit resistance or intolerance 
to current therapies and repositioning of a therapy with a known safety profile may reduce 
development costs.
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This study strengthens our previously reported GRS analysis indicating that all BP elevating 
alleles combined could increase systolic BP by 10 mm Hg or more across quintiles or 
deciles of the population distribution, substantially increasing risk of cardiovascular 
events10. We previously suggested that genotyping BP elevating variants in the young may 
lead to targeted lifestyle intervention in early life that might attenuate the BP rise at older 
ages10.
We identified several BP-associated loci that are also associated with lifestyle traits, 
suggesting shared genetic architecture between BP and lifestyle exposures 53. We adjusted 
our BP GWAS analyses for BMI to control for possible confounding effects, though we 
acknowledge the potential for collider bias54. Nonetheless, our findings of possible genetic 
overlap between loci associated with BP and lifestyle exposures could support renewed 
focus on altering specific lifestyle measures known to affect BP55.
Despite smaller sample sizes, we observed high concordance with direction of effects on BP 
traits of BP variants in Africans (> 62%) and South Asians (> 72%). The GRS analyses 
show that, in combination, BP variants identified in European analyses are associated with 
BP in non-European ancestries, though effect sizes were 30-40% smaller.
Our use of a two- and one-stage GWAS design illustrates the value of this approach to 
minimize the effects of stochastic variation and heterogeneity. The one-stage approach 
included signals that had independent and concordant support (P < 0.01) from both UKB 
and ICBP, reducing the impact of winners’ curse on our findings. Indeed, all but two of the 
210 SNPs discovered in the one-stage analysis reach P < 5 × 10-6 in either UKB or ICBP. To 
further minimize the risk of reporting false positive loci within our one-stage design, we set 
a stringent overall discovery meta-analysis P-value threshold of P < 5 × 10-9, an order of 
magnitude smaller than a genome-wide significance P-value, in line with thresholds 
recommended for whole genome sequencing22. We found high concordance in direction of 
effects between discovery data in the one-stage approach and the replication resources, with 
similar distributions of effect sizes for the two approaches. We note that 24 of the one-stage 
SNPs which reached P < 5 × 10-9 in discovery failed to reach genome-wide significance (P < 
5 × 10-8) in the combined meta-analysis of discovery and replication resources, and hence 
may still require further validation in future, larger studies.
The new discoveries reported here more than triple the number of loci for BP to a total of 
901 and represent a substantial advance in understanding the genetic architecture of BP. The 
identification of many novel genes across the genome, could partly support an omnigenic 
model for complex traits where genome-wide association of multiple interconnected 
pathways is observed. However, our strong tissue enrichment shows particular relevance to 
the biology of BP and cardiovascular disease56, suggesting trait-specificity, which could 
argue against an omnigenic model. Our confirmation of the impact of these variants on BP 
level and cardiovascular events, coupled with identification of shared risk variants for BP 
and adverse lifestyle could contribute to an early life precision medicine strategy for 
cardiovascular disease prevention.
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Online Methods
UK Biobank (UKB) data
We performed a Genome Wide Association Study (GWAS) analysis in 458,577 UKB 
participants13 (Supplementary Methods). These consist of 408,951 individuals from UKB 
genotyped at 825,927 variants with a custom Affymetrix UK Biobank Axiom Array chip 
and 49,626 individuals genotyped at 807,411 variants with a custom Affymetrix UK 
BiLEVE Axiom Array chip from the UK BiLEVE study57, which is a subset of UKB. SNPs 
were imputed centrally by UKB using a reference panel that merged the UK10K and 1000 
Genomes Phase 3 panel as well as the Haplotype Reference Consortium (HRC) panel58. For 
current analysis only SNPs imputed from the HRC panel were considered.
UKB phenotypic data—Following Quality Control (QC) (Supplementary Methods), we 
restricted our data to a subset of post-QC individuals of European ancestry combining 
information from self-reported and genetic data (Supplementary Methods) resulting in a 
maximum of N=458,577 individuals (Fig. 1, Supplementary Fig. 12).
Three BP traits were analysed: systolic (SBP), diastolic (DBP) and pulse pressure (PP) 
(difference between SBP and DBP). We calculated the mean SBP and DBP values from two 
automated (N=418,755) or two manual (N=25,888) BP measurements. For individuals with 
one manual and one automated BP measurement (N=13,521), we used the mean of these 
two values. For individuals with only one available BP measurement (N=413), we used this 
single value. After calculating BP values, we adjusted for medication use by adding 15 and 
10 mmHg to SBP and DBP, respectively, for individuals reported to be taking BP-lowering 
medication (N=94,289)59. Descriptive summary statistics are shown in Supplementary 
Table 1a.
UKB analysis models—For the UKB GWAS we performed linear mixed model (LMM) 
association testing under an additive genetic model of the three (untransformed) continuous, 
medication-adjusted BP traits (SBP, DBP, PP) for all measured and imputed genetic variants 
in dosage format using the BOLT-LMM (v2.3) software17. We also calculated the estimated 
SNP-wide heritability (h2) in our data. Within the association analysis, we adjust for the 
following covariates: sex, age, age2, BMI and a binary indicator variable for UKB vs UK 
BiLEVE to account for the different genotyping chips. The analysis of all HRC-imputed 
SNPs was restricted to variants with MAF ≥ 1% and INFO > 0.1.
Genomic inflation and confounding—We applied the univariate LD score regression 
method (LDSR)18 to test for genomic inflation (expected for polygenic traits like BP, with 
large sample sizes, and especially also from analyses of such dense genetic data with many 
SNPs in high LD)60. LDSR intercepts (and standard errors) were 1.217 (0.018), 1.219 
(0.020) and 1.185 (0.017) for SBP, DBP and PP respectively, and were used to adjust the 
UKB GWAS results for genomic inflation, prior to the meta-analysis.
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International Consortium for Blood Pressure (ICBP) GWAS
ICBP GWAS is an international consortium to investigate BP genetics6. We combined 
previously reported post-QC GWAS data from 54 studies (N=150,134)11,12,61, with newly 
available GWAS data from a further 23 independent studies (N=148,890) using a fixed 
effects inverse variance weighted meta-analysis. The 23 studies providing new data were: 
ASCOT-SC, ASCOT-UK, BRIGHT, Dijon 3C, EPIC-CVD, GAPP, HCS, GS:SFHS, 
Lifelines, JUPITER, PREVEND, TWINSUK, GWAS-Fenland, InterAct-GWAS, OMICS-
EPIC, OMICS-Fenland, UKHLS, GoDARTS-Illumina and GoDarts-Affymetrix, NEO, 
MDC, SardiNIA, METSIM.
All study participants were Europeans and were imputed to either the 1000 Genomes Project 
Phase 1 integrated release v.3 [March 2012] all ancestry reference panel62 or the HRC 
panel16. The final enlarged ICBP GWAS dataset included 77 cohorts (N=299,024).
Full study names, cohort information and general study methods are included in 
Supplementary Table 1b and in Supplementary Tables 20a-c. GC was applied at study-level. 
The LDSR intercepts (standard error) for the ICBP GWAS meta-analysis were 1.089 
(0.012), 1.086 (0.012) and 1.066 (0.011) for SBP, DBP and PP, respectively.
Meta-analyses of discovery datasets
We performed a fixed-effects inverse variance weighted meta-analysis using METAL20,63 
to obtain summary results from the UKB and ICBP GWAS, for up to N=757,601 
participants and ~7.1 M SNPs with MAF ≥ 1% for variants present in both the UKB data 
and ICBP meta-analysis for all three traits. The LDSR intercepts (standard error), in the 
discovery meta-analysis of UKB and ICBP were 1.156 (0.020), 1.160 (0.021) and 1.113 
(0.018) for SBP, DBP and PP respectively. The LDSR intercept (standard error), after the 
exclusion of all published BP variants (see below) in the discovery meta-analysis of UKB 
and ICBP was 1.090 (0.018), 1.097 (0.017) and 1.064 (0.015) for SBP, DBP and PP 
respectively, hence showing little inflation in the discovery GWAS after the exclusion of 
published loci (Supplementary Fig. 13). No further correction was applied to the discovery 
meta-analysis of UKB and ICBP GWAS.
Previously reported variants
We compiled from the peer-reviewed literature all 357 SNPs previously reported to be 
associated with BP at the time that our analysis was completed, that have been identified and 
validated as the sentinel SNP in primary analyses from previous BP genetic association 
studies. These 357 published SNPs correspond to 274 distinct loci, according to locus 
definition of: (i) SNPs within ±500kb distance of each other; (ii) SNPs in Linkage 
Disequilibrium (LD), using a threshold of r2 ≥ 0.1, calculated with PLINK (v2.0). We then 
augment this list to all SNPs present within our data, which are contained within these 274 
published BP loci, i.e. all SNPs which are located ±500kb from each of the 357 published 
SNPs and/or in LD with any of the 357 previously validated SNPs (r2 ≥ 0.1).
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Identification of novel signals: Two-stage and one-stage study designs
To identify novel signals of association with BP, two complementary study designs (which 
we term here “two-stage design” and “one-stage design”) were implemented in order to 
maximize the available data and minimize reporting of false positive associations.
Two-stage design: Overview
All of the following criteria had to be satisfied for a signal to be reported as a novel signal of 
association with BP using our two-stage design:
(i) the sentinel SNP shows significance (P < 1 × 10-6) in the discovery meta-
analysis of UKB and ICBP, with concordant direction of effect between UKB 
and ICBP;
(ii) the sentinel SNP is genome-wide significant (P < 5 × 10-8) in the combined 
meta-analysis of discovery and replication (MVP and EGCUT) (replication, 
described below);
(iii) the sentinel SNP shows support (P < 0.01) in the replication meta-analysis of 
MVP and EGCUT alone (Supplementary Methods);
(iv) the sentinel SNP has concordant direction of effect between the discovery and 
the replication meta-analyses;
(v) the sentinel SNP must not be located within any of the 274 previously reported 
loci described above.
The primary replicated trait was then defined as the BP trait with the most significant 
association from the combined meta-analysis of discovery and replication (in the case where 
a SNP was replicated for more than one BP trait.)
Two-stage design: Selection of variants from the discovery meta-analysis—We 
considered for follow-up SNPs in loci non-overlapping with previously reported loci 
according to both an LD threshold at r2 of 0.1 and a 1Mb interval region, as calculated by 
PLINK64. We obtained a list of such SNPs with P < 1 × 10-6 for any of the three BP traits, 
which also had concordant direction of effect between UKB vs ICBP (Supplementary Table 
21). By ranking the SNPs by significance in order of minimum P-value across all BP traits, 
we performed an iterative algorithm to determine the number of novel signals 
(Supplementary Methods), and identify the sentinel SNP (most significant) per locus.
Two-stage design: Replication analysis—We considered SNPs with MAF ≥ 1% for 
an independent replication in MVP (max N=220,520)14 and in EGCUT Biobank 
(N=28,742)15 (Supplementary Methods). This provides a total of N=249,262 independent 
samples of European descent available for replication. Additional information on the 
analyses of the two replication datasets is provided in Supplementary Methods and in 
Supplementary Table 1c.
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The two datasets were then combined using fixed effects inverse variance weighted meta-
analysis and summary results for all traits were obtained for the replication meta-analysis 
dataset.
Two-stage design: Combined meta-analysis of discovery and replication 
meta-analyses—The meta-analyses were performed within METAL software63 using 
fixed effects inverse variance weighted meta-analysis (Supplementary Methods). The 
variants from the discovery GWAS that required proxies for replication are shown in 
Supplementary Table 22. The combined meta-analysis of both the discovery data 
(N=757,601) and replication meta-analysis (max N=249,262) provided a maximum sample 
size of N=1,006,863.
One-stage design: Overview
Variants that were looked-up but did not replicate according to the two-stage criteria were 
considered in a one-stage design. All of the following criteria had to be satisfied for a signal 
to be reported as a novel signal of association with BP using our one-stage criteria:
i) the sentinel SNP has P < 5 × 10-9 in the discovery (UKB+ICBP) meta-analysis;
ii) the sentinel SNP shows support (P < 0.01) in the UKB GWAS alone;
iii) the sentinel SNP shows support (P < 0.01) in the ICBP GWAS alone;
iv) the sentinel SNP has concordant direction of effect between UKB and ICBP 
datasets;
v) The sentinel SNP must not be located within any of the 274 previously reported 
loci described above (Supplementary Table 4) or the recently reported non-
replicated loci from Hoffman et al9 (Supplementary Table 23).
We selected the one-stage P-value threshold to be an order of magnitude more stringent than 
a genome-wide significance P-value, so as to ensure robust results and to minimize false 
positive findings. The threshold of P < 5 × 10-9 has been proposed as a more conservative 
statistical significance threshold, e.g. for whole-genome sequencing-based studies21.
Selection of variants from the meta-analysis of UKB and ICBP was performed as described 
above for the two-stage design.
Conditional Analysis
We performed conditional analyses using the GWAS discovery meta-analysis data, in order 
to identify any independent secondary signals in addition to the sentinel SNPs at the 901 
loci. We used two different methodological approaches, each using the Genome-wide 
Complex Traits Analysis (GCTA) software22: (i) full “genome-wide conditional analysis” 
with joint multivariate analysis and stepwise model selection across all three BP traits; and 
(ii) “locus-specific conditional analysis” for the primary BP trait conditioning on the sentinel 
SNPs within each locus (Supplementary Methods). For robustness, secondary signals are 
only reported if obtained from both approaches. All secondary signals were selected at 
genome-wide significance level, with MAF ≥ 1% and confirmed to be pairwise-LD-
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independent (r2 < 0.1), as well as not being in LD with any of the published or sentinel SNPs 
at any of the 901 BP-associated loci (r2 < 0.1). In all cases the UKB data was used as the 
reference genetic data for LD calculation, restricted to individuals of European ancestry 
only.
Functional analyses: Variants
We used an integrative bioinformatics approach to collate functional annotation at both the 
variant level (for each sentinel SNP within all BP loci) and the gene level (using SNPs in LD 
r2 ≥ 0.8 with the sentinel SNPs). At the variant level, we use Variant Effect Predictor (VEP) 
to obtain comprehensive characterization of variants, including consequence (e.g. 
downstream or non-coding transcript exon), information on nearest genomic features and, 
where applicable, amino acid substitution functional impact, based on SIFT and PolyPhen. 
The biomaRt R package is used to further annotate the nearest genes.
We evaluated all SNPs in LD (r2 ≥ 0.8) with our novel sentinel SNPs for evidence of 
mediation of expression quantitative trait loci (eQTL) in all 44 tissues using the Genotype-
Tissue Expression (GTEx) database, to highlight specific tissue types which show eQTLs for 
a larger than expected proportion of novel loci. We further seek to identify novel loci with 
the strongest evidence of eQTL associations in arterial tissue, in particular. A locus is 
annotated with a given eGene only if the most significant eQTL SNP for the given eGene is 
in high LD (r2 ≥ 0.8) with the sentinel SNP, suggesting that the eQTL signal co-localises 
with the sentinel SNP.
We annotated nearest genes, eGenes (genes whose expression is affected by eQTLs) and Hi-
C interactors with HUVEC, HVMSC and HAEC expression from the Fantom5 project. 
Genes that had higher than median expression levels in the given cell types were indicated as 
expressed.
To identify SNPs in the novel loci that have a non-coding functional effect (influence 
binding of transcription factors or RNA polymerase, or influence DNase hypersensitivity 
sites or histone modifications), we used DeepSEA, a deep learning algorithm, that learnt the 
binding and modification patterns of ~900 cell/factor combinations65. A change of >0.1 in 
the binding score predicted by DeepSEA for the reference and alternative alleles respectively 
was used as cut-off to find alleles with non-coding functional effect (Supplementary 
Methods)
We identified potential target genes of regulatory SNPs using long-range chromatin 
interaction (Hi-C) data from HUVECs23, aorta, adrenal glands, neural progenitor and 
mesenchymal stem cell, which are tissues and cell types that are considered relevant for 
regulating BP24. We find the most significant promoter interactions for all potential 
regulatory SNPs (RegulomeDB score ≤ 5) in LD (r2 ≥ 0.8) with our novel sentinel SNPs and 
published SNPs, and choose the interactors with the SNPs of highest regulatory potential to 
annotate the loci.
We then performed overall enrichment testing across all loci. Firstly, we used DEPICT66 
(Data-driven Expression Prioritized Integration for Complex Traits) to identify tissues and 
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cells which are highly expressed at genes within the BP loci (Supplementary Methods). 
Secondly, we used DEPICT to test for enrichment in gene sets associated with biological 
annotations (manually curated and molecular pathways, phenotype data from mouse KO 
studies) (Supplementary Methods). We report significant enrichments with a false discovery 
rate <0.01. The variants tested were i) the 357 published BP associated SNPs at the time of 
analysis and ii) a set including all (published and novel) variants (with novel SNPs filtered 
by highest significance, P < 1 × 10-12).
Furthermore, to investigate cell type specific enrichment within DNase I sites, we used 
FORGE, which tests for enrichment of SNPs within DNase I sites in 123 cell types from the 
Epigenomics Roadmap Project and ENCODE25 (Supplementary Methods). Two analyses 
were compared (i) using published SNPs only; (ii) using sentinel SNPs at all 901 loci, in 
order to evaluate the overall tissue specific enrichment of BP associated variants.
Functional analyses: Genes
At the gene level, we used Ingenuity Pathway Analysis (IPA) software (IPA®, QIAGEN 
Redwood City) to review genes with prior links to BP, based on annotation with the 
“Disorder of Blood Pressure”, “Endothelial Development” and “Vascular Disease” Medline 
Subject Heading (MESH) terms. We used the Mouse Genome Informatics (MGI) tool to 
identify BP and cardiovascular relevant mouse knockout phenotypes for all genes linked to 
BP in our study. We also used IPA to identify genes that interact with known targets of anti-
hypertensive drugs. Genes were also evaluated for evidence of small molecule druggability 
or known drugs based on queries of the Drug Gene Interaction database.
Lookups in non-European ancestries
As a secondary analysis, we look up all known and novel BP-associated SNPs in Africans 
(7,782) and South Asians (10,322) from UKB using BOLT-LMM analysis for each BP trait 
within each ancestry (Supplementary Methods).
Effects on other traits and diseases
We queried SNPs against GWAS catalog26 and PhenoScanner27, including genetics and 
metabolomics databases, to investigate cross-trait effects, extracting all association results 
with genome-wide significance at P < 5 × 10-8 for all SNPs in high LD (r2 ≥ 0.8) with the 
535 sentinel novel SNPs, to highlight the loci with strongest evidence of association with 
other traits. We further evaluated these effects using DisGeNET28,29. At the gene level, 
overrepresentation enrichment analysis (ORA) with WebGestalt67 on the nearest genes to all 
BP loci was carried out. Moreover, we tested sentinel SNPs at all published and novel 
(N=901) loci for association with lifestyle related data including food, water and alcohol 
intake, anthropomorphic traits and urinary sodium, potassium and creatinine excretion using 
the recently developed Stanford Global Biobank Engine and the Gene ATLAS68. Both are 
search engines for GWAS findings for multiple phenotypes in UK Biobank. We used a 
Bonferroni corrected significance threshold of P < 1 × 10-6 to deem significance.
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Genetic risk scores and percentage of variance explained
We calculated a weighted genetic risk score (GRS) (Supplementary Table 24) to provide an 
estimate of the combined effect of the BP raising variants on BP and risk of hypertension 
and applied this to the UKB data (Supplementary Methods). Our analysis included 423,713 
unrelated individuals of European ancestry of whom 392,092 individuals were free of 
cardiovascular events at baseline.
We assessed the association of the continuous GRS variable on BP and with the risk of 
hypertension, with and without adjustment for sex. We then compared BP levels and risk of 
hypertension, respectively, for individuals in the top vs bottom quintiles of the GRS 
distribution. Similar analyses were performed for the top vs bottom deciles of the GRS 
distribution. All analyses were restricted to the 392,092 unrelated individuals of European 
ancestry from UKB. As a sensitivity analysis to assess for evidence of bias in the UKB 
results, we also carried out similar analyses in Airwave, an independent cohort of N=14,004 
unrelated participants of European descent30 (Supplementary Methods).
We calculated the association of the GRS with cardiovascular disease in unrelated 
participants in UKB data, based on self-reported medical history, and linkage to 
hospitalization and mortality data (Supplementary Table 25). We use logistic regression with 
binary outcome variables for composite incident cardiovascular disease (Supplementary 
Methods), incident myocardial infarction and incident stroke (using the algorithmic UKB 
definitions) and GRS as explanatory variable (with and without sex adjustment).
We also assessed the association of this GRS with BP in unrelated individuals Africans 
(N=6,970) and South Asians (N=8,827) from the UKB to see whether BP-associated SNPs 
identified from GWAS predominantly in Europeans are also associated with BP in 
populations of non-European ancestry.
We calculated the percentage of variance in BP explained by genetic variants using the 
independent Airwave cohort (N=14,004) (Supplementary Methods). We considered three 
different levels of the GRS: (i) all pairwise-independent, LD-filtered (r2 < 0.1) published 
SNPs within the known loci; (ii) all known SNPs and sentinel SNPs at novel loci; (iii) all 
independent signals at all 901 known and novel loci including the 163 secondary SNPs.
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Refer to Web version on PubMed Central for supplementary material.
Authors 
Evangelos Evangelou#1,2, Helen R Warren#3,4, David Mosen-Ansorena#1, Borbala 
Mifsud#3, Raha Pazoki#1, He Gao#1,5, Georgios Ntritsos#2, Niki Dimou#2, Claudia P 
Cabrera3,4, Ibrahim Karaman1, Fu Liang Ng3, Marina Evangelou1,6, Katarzyna 
Witkowska3, Evan Tzanis3, Jacklyn N Hellwege7, Ayush Giri8, Digna R Velez 
Edwards8, Yan V Sun9,10, Kelly Cho11,12, J.Michael Gaziano11,12, Peter WF 
Wilson13, Philip S Tsao14, Csaba P Kovesdy15, Tonu Esko16,17, Reedik Mägi16, Lili 
Milani16, Peter Almgren18, Thibaud Boutin19, Stéphanie Debette20,21, Jun Ding22, 
Evangelou et al. Page 16
Nat Genet. Author manuscript; available in PMC 2018 December 07.
 E
urope PM
C
 Funders A
uthor M
anuscripts
 E
urope PM
C
 Funders A
uthor M
anuscripts
Franco Giulianini23, Elizabeth G Holliday24, Anne U Jackson25, Ruifang Li-Gao26, 
Wei-Yu Lin27, Jian'an Luan28, Massimo Mangino29,30, Christopher Oldmeadow24, 
Bram Peter Prins31, Yong Qian22, Muralidharan Sargurupremraj21, Nabi Shah32,33, 
Praveen Surendran27, Sébastien Thériault34,35, Niek Verweij17,36,37, Sara M 
Willems28, Jing-Hua Zhao28, Philippe Amouyel38, John Connell39, Renée de 
Mutsert26, Alex SF Doney32, Martin Farrall40,41, Cristina Menni29, Andrew D 
Morris42, Raymond Noordam43, Guillaume Paré34, Neil R Poulter44, Denis C 
Shields45, Alice Stanton46, Simon Thom47, Gonçalo Abecasis48, Najaf Amin49, Dan 
E Arking50, Kristin L Ayers51,52, Caterina M Barbieri53, Chiara Batini54, Joshua C 
Bis55, Tineka Blake54, Murielle Bochud56, Michael Boehnke25, Eric Boerwinkle57, 
Dorret I Boomsma58, Erwin P Bottinger59, Peter S Braund60,61, Marco Brumat62, 
Archie Campbell63,64, Harry Campbell65, Aravinda Chakravarti50, John C 
Chambers1,5,66,67,68, Ganesh Chauhan69, Marina Ciullo70,71, Massimiliano 
Cocca72, Francis Collins73, Heather J Cordell51, Gail Davies74,75, Martin H de 
Borst76, Eco J de Geus58, Ian J Deary74,75, Joris Deelen77, M Fabiola Del Greco78, 
Cumhur Yusuf Demirkale79, Marcus Dörr80,81, Georg B Ehret50,82, Roberto 
Elosua83,84, Stefan Enroth85, A Mesut Erzurumluoglu54, Teresa Ferreira86,87, 
Mattias Frånberg88,89,90, Oscar H Franco91, Ilaria Gandin62, Paolo Gasparini62,72, 
Vilmantas Giedraitis92, Christian Gieger93,94,95, Giorgia Girotto62,72, Anuj Goel40,41, 
Alan J Gow74,96, Vilmundur Gudnason97,98, Xiuqing Guo99, Ulf Gyllensten85, 
Anders Hamsten88,89, Tamara B Harris100, Sarah E Harris63,74, Catharina A 
Hartman101, Aki S Havulinna102,103, Andrew A Hicks78, Edith Hofer104,105, Albert 
Hofman91,106, Jouke-Jan Hottenga58, Jennifer E Huffman19,107,108, Shih-Jen 
Hwang107,108, Erik Ingelsson109,110, Alan James111,112, Rick Jansen113, Marjo-
Riitta Jarvelin1,5,114,115,116, Roby Joehanes107,117, Åsa Johansson85, Andrew D 
Johnson107,118, Peter K Joshi65, Pekka Jousilahti102, J Wouter Jukema119, Antti 
Jula102, Mika Kähönen120,121, Sekar Kathiresan17,36,122, Bernard D Keavney123,124, 
Kay-Tee Khaw125, Paul Knekt102, Joanne Knight126, Ivana Kolcic127, Jaspal S 
Kooner5,67,68,128, Seppo Koskinen102, Kati Kristiansson102, Zoltan Kutalik56,129, 
Maris Laan130, Marty Larson107, Lenore J Launer100, Benjamin Lehne1, Terho 
Lehtimäki131,132, David CM Liewald74,75, Li Lin82, Lars Lind133, Cecilia M 
Lindgren40,87,134, YongMei Liu135, Ruth JF Loos28,59,136, Lorna M Lopez74,137,138, 
Yingchang Lu59, Leo-Pekka Lyytikäinen131,132, Anubha Mahajan40, Chrysovalanto 
Mamasoula139, Jaume Marrugat83, Jonathan Marten19, Yuri Milaneschi140, Anna 
Morgan62, Andrew P Morris40,141, Alanna C Morrison142, Peter J Munson79, Mike A 
Nalls143,144, Priyanka Nandakumar50, Christopher P Nelson60,61, Teemu 
Niiranen102,145, Ilja M Nolte146, Teresa Nutile70, Albertine J Oldehinkel147, Ben A 
Oostra49, Paul F O'Reilly148, Elin Org16, Sandosh Padmanabhan64,149, Walter 
Palmas150, Aarno Palotie103,151,152, Alison Pattie75, Brenda WJH Penninx140, 
Markus Perola102,103,153, Annette Peters94,95,154, Ozren Polasek127,155, Peter P 
Pramstaller78,156,157, Quang Tri Nguyen79, Olli T Raitakari158,159, Meixia Ren160, 
Rainer Rettig161, Kenneth Rice162, Paul M Ridker23,163, Janina S Ried94, Harriëtte 
Riese147, Samuli Ripatti103,164, Antonietta Robino72, Lynda M Rose23, Jerome I 
Rotter99, Igor Rudan165, Daniela Ruggiero70,71, Yasaman Saba166, Cinzia F Sala53, 
Veikko Salomaa102, Nilesh J Samani60,61, Antti-Pekka Sarin103, Reinhold 
Evangelou et al. Page 17
Nat Genet. Author manuscript; available in PMC 2018 December 07.
 E
urope PM
C
 Funders A
uthor M
anuscripts
 E
urope PM
C
 Funders A
uthor M
anuscripts
Schmidt104, Helena Schmidt166, Nick Shrine54, David Siscovick167, Albert V 
Smith97,98, Harold Snieder146, Siim Sõber130, Rossella Sorice70, John M 
Starr74,168, David J Stott169, David P Strachan170, Rona J Strawbridge88,89, Johan 
Sundström133, Morris A Swertz171, Kent D Taylor99, Alexander Teumer81,172, Martin 
D Tobin54, Maciej Tomaszewski123,124, Daniela Toniolo53, Michela Traglia53, Stella 
Trompet119,173, Jaakko Tuomilehto174,175,176,177, Christophe Tzourio21, André G 
Uitterlinden91,178, Ahmad Vaez146,179, Peter J van der Most146, Cornelia M van 
Duijn49, Anne-Claire Vergnaud1, Germaine C Verwoert91, Veronique Vitart19, Uwe 
Völker81,180, Peter Vollenweider181, Dragana Vuckovic62,182, Hugh Watkins40,41, 
Sarah H Wild183, Gonneke Willemsen58, James F Wilson19,65, Alan F Wright19, Jie 
Yao99, Tatijana Zemunik184, Weihua Zhang1,67, John R Attia24, Adam S 
Butterworth27,185, Daniel I Chasman23,163, David Conen186,187, Francesco 
Cucca188,189, John Danesh27,185, Caroline Hayward19, Joanna MM Howson27, 
Markku Laakso190, Edward G Lakatta191, Claudia Langenberg28, Olle Melander18, 
Dennis O Mook-Kanamori26,192, Colin NA Palmer32, Lorenz Risch193,194,195, Robert 
A Scott28, Rodney J Scott24, Peter Sever128, Tim D Spector29, Pim van der 
Harst196, Nicholas J Wareham28, Eleftheria Zeggini31, Daniel Levy107,118, Patricia B 
Munroe3,4, Christopher Newton-Cheh134,197,198, Morris J Brown3,4, Andres 
Metspalu16, Adriana M Hung199, Christopher J O’Donnell200, Todd L Edwards7, on 
behalf of the Million Veteran Program, Bruce M. Psaty201,202, Ioanna Tzoulaki#1,2,5, 
Michael R Barnes#3,4, Louise V Wain#54, Paul Elliott#1,5,203,204,205,‡, and Mark J 
Caulfield#3,4,‡
Affiliations
1Department of Epidemiology and Biostatistics, Imperial College London, London, 
UK 2Department of Hygiene and Epidemiology, University of Ioannina Medical 
School, Ioannina, Greece 3William Harvey Research Institute, Barts and The 
London School of Medicine and Dentistry, Queen Mary University of London, 
London, UK 4National Institute for Health Research, Barts Cardiovascular 
Biomedical Research Center, Queen Mary University of London, London, UK 
5MRC-PHE Centre for Environment and Health, Imperial College London, London, 
UK 6Department of Mathematics, Imperial College London, London, UK 7Division of 
Epidemiology, Department of Medicine, Institute for Medicine and Public Health, 
Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Tennessee 
Valley Healthcare System (626)/Vanderbilt University, Nashville, TN, USA 
8Vanderbilt Genetics Institute, Vanderbilt Epidemiology Center, Department of 
Obstetrics and Gynecology, Vanderbilt University Medical Center; Tennessee Valley 
Health Systems VA, Nashville, TN, USA 9Department of Epidemiology, Emory 
University Rollins School of Public Health, Atlanta, GA, USA 10Department of 
Biomedical Informatics, Emory University School of Medicine, Atlanta, GA, USA 
11Massachusetts Veterans Epidemiology Research and Information Center 
(MAVERIC), VA Boston Healthcare System, Boston, USA 12Division of Aging, 
Department of Medicine, Brigham and Women’s Hospital, Boston, MA, Department 
of Medicine, Harvard Medical School, Boston, MA, USA 13Atlanta VAMC and Emory 
Clinical Cardiovascular Research Institute, Atlanta, GA, USA 14VA Palo Alto Health 
Evangelou et al. Page 18
Nat Genet. Author manuscript; available in PMC 2018 December 07.
 E
urope PM
C
 Funders A
uthor M
anuscripts
 E
urope PM
C
 Funders A
uthor M
anuscripts
Care System; Division of Cardiovascular Medicine, Stanford University School of 
Medicine, CA, USA 15Nephrology Section, Memphis VA Medical Center and 
University of Tennessee Health Science Center, Memphis, TN, USA 16Estonian 
Genome Center, University of Tartu, Tartu, Estonia 17Program in Medical and 
Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA 
18Department Clinical Sciences, Malmö, Lund University, Malmö, Sweden 19MRC 
Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University 
of Edinburgh, Western General Hospital, Edinburgh, Scotland, UK 20Department of 
Neurology, Bordeaux University Hospital, Bordeaux, France 21Univ. Bordeaux, 
Inserm, Bordeaux Population Health Research Center, CHU Bordeaux, Bordeaux, 
France 22Laboratory of Genetics and Genomics, NIA/NIH, Baltimore, MD, USA 
23Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, 
USA 24Hunter Medical Reseach Institute and Faculty of Health, University of 
Newcastle, New Lambton Heights, New South Wales, Australia 25Department of 
Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, 
MI, USA 26Department of Clinical Epidemiology, Leiden University Medical Center, 
Leiden, the Netherlands 27MRC/BHF Cardiovascular Epidemiology Unit, 
Department of Public Health and Primary Care, University of Cambridge, 
Cambridge, UK 28MRC Epidemiology Unit, University of Cambridge School of 
Clinical Medicine, Cambridge, UK 29Department of Twin Research and Genetic 
Epidemiology, Kings College London, London, UK 30NIHR Biomedical Research 
Centre at Guy’s and St Thomas’ Foundation Trust, London, UK 31Wellcome Trust 
Sanger Institute, Hinxton, UK 32Division of Molecular and Clinical Medicine, School 
of Medicine, University of Dundee, UK 33Department of Pharmacy, COMSATS 
Institute of Information Technology, Abbottabad, Pakistan 34Department of 
Pathology and Molecular Medicine, McMaster University, Hamilton, Canada 
35Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval, 
Quebec City, Canada 36Cardiovascular Research Center and Center for Human 
Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, MA, 
USA 37University of Groningen, University Medical Center Groningen, Department 
of Cardiology, Groningen, The Netherlands 38University of Lille, Inserm, Centre 
Hosp. Univ Lille, Institut Pasteur de Lille, UMR1167 - RID-AGE - Risk factors and 
molecular determinants of aging-related diseases, Epidemiology and Public Health 
Department, Lille, France 39University of Dundee, Ninewells Hospital & Medical 
School, Dundee, UK 40Wellcome Trust Centre for Human Genetics, University of 
Oxford, Oxford, UK 41Division of Cardiovascular Medicine, Radcliffe Department of 
Medicine, University of Oxford, Oxford, UK 42Usher Institute of Population Health 
Sciences and Informatics, University of Edinburgh, UK 43Department of Internal 
Medicine, Section Gerontology and Geriatrics, Leiden University Medical Center, 
Leiden, The Netherlands 44Imperial Clinical Trials Unit, Stadium House, 68 Wood 
Lane, London, UK 45School of Medicine, University College Dublin, Ireland 
46Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, 
Ireland 47International Centre for Circulatory Health, Imperial College London, 
London, UK 48Center for Statistical Genetics, Dept. of Biostatistics, SPH II, 
Evangelou et al. Page 19
Nat Genet. Author manuscript; available in PMC 2018 December 07.
 E
urope PM
C
 Funders A
uthor M
anuscripts
 E
urope PM
C
 Funders A
uthor M
anuscripts
Washington Heights, Ann Arbor, MI, USA 49Genetic Epidemiology Unit, Department 
of Epidemiology, Erasmus MC, Rotterdam, the Netherlands 50Center for Complex 
Disease Genomics, McKusick-Nathans Institute of Genetic Medicine, Johns 
Hopkins University School of Medicine, Baltimore, MD, USA 51Institute of Genetic 
Medicine, Newcastle University, Newcastle upon Tyne, UK 52Sema4, a Mount Sinai 
venture, Stamford, CT, USA 53Division of Genetics and Cell Biology, San Raffaele 
Scientific Institute, Milano, Italy 54Department of Health Sciences, University of 
Leicester, Leicester, UK 55Cardiovascular Health Research Unit, Department of 
Medicine, University of Washington, Seattle, WA, USA 56Institute of Social and 
Preventive Medicine, University Hospital of Lausanne, Lausanne, Switzerland 
57Human Genetics Center, School of Public Health, The University of Texas Health 
Science Center at Houston and Human Genome Sequencing Center, Baylor 
College of Medicine, One Baylor Plaza, Houston, TX, USA 58Department of 
Biological Psychology, Vrije Universiteit Amsterdam, EMGO+ institute, VU 
University medical center, Amsterdam, the Netherlands 59The Charles Bronfman 
Institute for Personalized Medicine, Icachn School of Medicine at Mount Sinai, NY, 
USA 60Department of Cardiovascular Sciences, University of Leicester, Leicester, 
UK 61 NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Groby Road, 
Leicester, UK 62Department of Medical, Surgical and Health Sciences, University of 
Trieste, Trieste, Italy 63Medical Genetics Section, Centre for Genomic and 
Experimental Medicine, Institute of Genetics and Molecular Medicine, University of 
Edinburgh, Edinburgh, UK 64Generation Scotland, Centre for Genomic and 
Experimental Medicine, University of Edinburgh, Edinburgh, UK 65Centre for Global 
Health Research, Usher Institute of Population Health Sciences and Informatics, 
University of Edinburgh, Edinburgh, Scotland, UK 66Lee Kong Chian School of 
Medicine, Nanyang Technological University, Singapore, Singapore 67Department of 
Cardiology, Ealing Hospital, Middlesex, UK 68Imperial College Healthcare NHS 
Trust, London, UK 69Centre for Brain Research, Indian Institute of Science, 
Bangalore, India 70Institute of Genetics and Biophysics "A. Buzzati-Traverso", CNR, 
Napoli, Italy 71IRCCS Neuromed, Pozzilli, Isernia, Italy 72Institute for Maternal and 
Child Health IRCCS Burlo Garofolo, Trieste, Italy 73Medical Genomics and Metabolic 
Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD, 
USA 74Centre for Cognitive Ageing and Cognitive Epidemiology, University of 
Edinburgh, 7 George Square, Edinburgh, UK 75Department of Psychology, 
University of Edinburgh, 7 George Square, Edinburgh, UK 76Department of Internal 
Medicine, Division of Nephrology, University of Groningen, University Medical 
Center Groningen, Groningen, The Netherlands 77Department of Molecular 
Epidemiology, Leiden University Medical Center, Leiden, the Netherlands 78Institute 
for Biomedicine, Eurac Research, Bolzano, Italy - Affiliated Institute of the University 
of Lübeck, Lübeck, Germany 79Mathematical and Statistical Computing Laboratory, 
Office of Intramural Research, Center for Information Technology, National Institutes 
of Health, Bethesda, MD, USA 80Department of Internal Medicine B, University 
Medicine Greifswald, Greifswald, Germany 81DZHK (German Centre for 
Cardiovascular Research), partner site Greifswald, Greifswald, Germany 
Evangelou et al. Page 20
Nat Genet. Author manuscript; available in PMC 2018 December 07.
 E
urope PM
C
 Funders A
uthor M
anuscripts
 E
urope PM
C
 Funders A
uthor M
anuscripts
82Cardiology, Department of Medicine, Geneva University Hospital, Geneva, 
Switzerland 83CIBERCV & Cardiovascular Epidemiology and Genetics, IMIM. Dr 
Aiguader 88, Barcelona, Spain 84Faculty of Medicine, Universitat de Vic-Central de 
Catalunya, Vic, Spain 85Department of Immunology, Genetics and Pathology, 
Uppsala Universitet, Science for Life Laboratory, Uppsala, Sweden 86Wellcome 
Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, UK 87Big 
Data Institute, Li Ka Shing Center for Health for Health Information and Discovery, 
Oxford University, Old Road, Oxford, UK 88Cardiovascular Medicine Unit, 
Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden 89Centre 
for Molecular Medicine, L8:03, Karolinska Universitetsjukhuset, Solna, Sweden 
90Department of Numerical Analysis and Computer Science, Stockholm University, 
Stockholm, Sweden 91Department of Epidemiology, Erasmus MC, Rotterdam, the 
Netherlands 92Department of Public Health and Caring Sciences, Geriatrics, 
Uppsala, Sweden 93Research Unit of Molecular Epidemiology, Helmholtz Zentrum 
München, German Research Center for Environmental Health, Neuherberg, 
Germany 94Institute of Epidemiology, Helmholtz Zentrum München, German 
Research Center for Environmental Health, Neuherberg, Germany 95German 
Center for Diabetes Research (DZD e.V.), Neuherberg, Germany 96Department of 
Psychology, School of Social Sciences, Heriot-Watt University, Edinburgh, UK 
97Faculty of Medicine, University of Iceland, Reykjavik, Iceland 98Icelandic Heart 
Association, Kopavogur, Iceland 99The Institute for Translational Genomics and 
Population Sciences, Department of Pediatrics, LABioMed at Harbor-UCLA Medical 
Center, Torrance, CA, USA 100Intramural Research Program, Laboratory of 
Epidemiology, Demography, and Biometry, National Institute on Aging, Bethesda, 
MD, USA 101Department of Psychiatry, University of Groningen, University Medical 
Center Groningen, Groningen, The Netherlands 102Department of Public Health 
Solutions, National Institute for Health and Welfare (THL), Helsinki, Finland 
103Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, 
Finland 104Clinical Division of Neurogeriatrics, Department of Neurology, Medical 
University of Graz, Graz, Austria 105Institute for Medical Informatics, Statistics and 
Documentation, Medical University of Graz, Graz, Austria 106Department of 
Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA 
107National Heart, Lung and Blood Institute's Framingham Heart Study, 
Framingham, MA, USA 108The Population Science Branch, Division of Intramural 
Research, National Heart Lung and Blood Institute national Institute of Health, 
Bethesda, MD, USA 109Department of Medical Sciences, Molecular Epidemiology 
and Science for Life Laboratory, Uppsala University, Uppsala, Sweden 110Division of 
Cardiovascular Medicine, Department of Medicine, Stanford University School of 
Medicine, Stanford, CA USA 111Department of Pulmonary Physiology and Sleep, Sir 
Charles Gairdner Hospital, Hospital Avenue, Nedlands, Australia 112School of 
Medicine and Pharmacology, University of Western Australia 113Department of 
Psychiatry, VU University Medical Center, Amsterdam Neuroscience, Amsterdam, 
the Netherlands 114Biocenter Oulu, University of Oulu, Oulu, Finland 115Center For 
Life-course Health Research, University of Oulu, Oulu Finland 116Unit of Primary 
Evangelou et al. Page 21
Nat Genet. Author manuscript; available in PMC 2018 December 07.
 E
urope PM
C
 Funders A
uthor M
anuscripts
 E
urope PM
C
 Funders A
uthor M
anuscripts
Care, Oulu University Hospital, Oulu, Oulu, Finland 117Hebrew SeniorLife, Harvard 
Medical School, Boston, MA, USA 118Population Sciences Branch, National Heart, 
Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA 
119Department of Cardiology, Leiden University Medical Center, Leiden, the 
Netherlands 120Department of Clinical Physiology, Tampere University Hospital, 
Tampere, Finland 121Department of Clinical Physiology, Finnish Cardiovascular 
Research Center - Tampere, Faculty of Medicine and Life Sciences, University of 
Tampere, Tampere, Finland 122Broad Institute of the Massachusetts Institute of 
Technology and Harvard University, Cambridge, MA, USA 123Division of 
Cardiovascular Sciences, Faculty of Biology, Medicine and Health, The University of 
Manchester, Manchester, UK 124Division of Medicine, Manchester University NHS 
Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK 
125Department of Public Health and Primary Care, Institute of Public Health, 
University of Cambridge, Cambridge, UK 126Data Science Institute and Lancaster 
Medical School, Lancaster, UK 127Department of Public Health, Faculty of Medicine, 
University of Split, Croatia 128National Heart and Lung Institute, Imperial College 
London, London, UK 129Swiss Institute of Bioinformatics, Lausanne, Switzerland 
130Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, 
Estonia 131Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland 
132Department of Clinical Chemistry, Finnish Cardiovascular Research Center - 
Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, 
Finland 133Department of Medical Sciences, Cardiovascular Epidemiology, Uppsala 
University, Uppsala, Sweden 134Program in Medical and Population Genetics, Broad 
Institute, Cambridge, MA, USA 135Division of Public Health Sciences, Wake Forest 
School of Medicine, Winston-Salem, NC, USA 136Mindich Child health Development 
Institute, The Icahn School of Medicine at Mount Sinai, New York, NY, USA 
137Department of Psychiatry, Royal College of Surgeons in Ireland, Education and 
Research Centre, Beaumont Hospital, Dublin, Ireland 138University College Dublin, 
UCD Conway Institute, Centre for Proteome Research, UCD, Belfield, Dublin, 
Ireland 139Institute of Health and Society, Newcastle University, Newcastle upon 
Tyne, UK 140Department of Psychiatry, Amsterdam Public Health and Amsterdam 
Neuroscience, VU University Medical Center/GGZ inGeest, Amsterdam, The 
Netherlands 141Department of Biostatistics, University of Liverpool, Block F, 
Waterhouse Building, Liverpool, UK 142Department of Epidemiology, Human 
Genetics and Environmental Sciences, School of Public Health, University of Texas 
Health Science Center at Houston, Houston, TX, USA 143Data Tecnica International, 
Glen Echo, MD, USA 144Laboratory of Neurogenetics, National Institute on Aging, 
Bethesda, USA 145Department of Medicine, Turku University Hospital and University 
of Turku, Finland 146Department of Epidemiology, University of Groningen, 
University Medical Center Groningen, Groningen, The Netherlands 
147Interdisciplinary Center Psychopathology and Emotion regulation (ICPE), 
University of Groningen, University Medical Center Groningen, Groningen, The 
Netherlands 148SGDP Centre, Institute of Psychiatry, Psychology and 
Neuroscience, King's College London, London, UK 149British Heart Foundation 
Evangelou et al. Page 22
Nat Genet. Author manuscript; available in PMC 2018 December 07.
 E
urope PM
C
 Funders A
uthor M
anuscripts
 E
urope PM
C
 Funders A
uthor M
anuscripts
Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical 
Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, 
Glasgow, UK 150Department of Medicine, Columbia University Medical Center, New 
York, NY, USA 151Analytic and Translational Genetics Unit, Department of Medicine, 
Department of Neurology and Department of Psychiatry Massachusetts General 
Hospital, Boston, MA, USA 152The Stanley Center for Psychiatric Research and 
Program in Medical and Population Genetics, The Broad Institute of MIT and 
Harvard, Cambridge, MA, USA 153University of Tartu, Tartu, Estonia 154German 
Center for Cardiovascular Disease Research (DZHK), partner site Munich, 
Neuherberg, Germany 155Psychiatric hospital “Sveti Ivan”, Zagreb, Croatia 
156Department of Neurology, General Central Hospital, Bolzano, Italy 157Department 
of Neurology, University of Lübeck, Lübeck, Germany 158Department of Clinical 
Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland 
159Research Centre of Applied and Preventive Cardiovascular Medicine, University 
of Turku, Turku, Finland 160Fujian Key Laboratory of Geriatrics, Department of 
Geriatric Medicine, Fujian Provincial Hospital, Fujian Medical University, Fuzhou, 
China 161Institute of Physiology, University Medicine Greifswald, Karlsburg, 
Germany 162Department of Biostatistics University of Washington, Seattle, WA, USA 
163Harvard Medical School, Boston MA 164Public health, Faculty of Medicine, 
University of Helsinki, Finland 165Centre for Global Health Research, Usher Institute 
of Population Health Sciences and Informatics, University of Edinburgh, Scotland, 
UK 166Gottfried Schatz Research Center for Cell Signaling, Metabolism & Aging, 
Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria 
167The New York Academy of Medicine, New York, NY, USA 168Alzheimer Scotland 
Dementia Research Centre, University of Edinburgh, Edinburgh, UK 169Institute of 
Cardiovascular and Medical Sciences, Faculty of Medicine, University of Glasgow, 
United Kingdom 170Population Health Research Institute, St George's, University of 
London, London, UK 171Department of Genetics, University of Groningen, University 
Medical Center Groningen, Groningen, The Netherlands 172Institute for Community 
Medicine, University Medicine Greifswald, Greifswald, Germany 173Department of 
Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the 
Netherlands 174Dasman Diabetes Institute, Dasman, Kuwait 175Chronic Disease 
Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland 
176Department of Public Health, University of Helsinki, Helsinki, Finland 177Saudi 
Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia 
178Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands 
179Research Institute for Primordial Prevention of Non-communicable Disease, 
Isfahan University of Medical Sciences, Isfahan, Iran 180Interfaculty Institute for 
Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, 
Germany 181Department of Internal Medicine, University Hospital, CHUV, Lausanne, 
Switzerland 182Experimental Genetics Division, Sidra Medical and Research Center, 
Doha, Qatar 183Centre for Population Health Sciences, Usher Institute of Population 
Health Sciences and Informatics, University of Edinburgh, Scotland, UK 
184Department of Biology, Faculty of Medicine, University of Split, Croatia 185The 
Evangelou et al. Page 23
Nat Genet. Author manuscript; available in PMC 2018 December 07.
 E
urope PM
C
 Funders A
uthor M
anuscripts
 E
urope PM
C
 Funders A
uthor M
anuscripts
National Institute for Health Research Blood and Transplant Research Unit in Donor 
Health and Genomics, University of Cambridge, UK 186Division of Cardiology, 
University Hospital, Basel, Switzerland 187Division of Cardiology, Department of 
Medicine, McMaster University, Hamilton, Canada 188Institute of Genetic and 
Biomedical Research, National Research Council (CNR), Monserrato, Cagliari, Italy 
189Department of Biomedical Sciences, University of Sassari, Sassari, Italy 
190Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland and 
Kuopio University Hospital, Kuopio, Finland 191Laboratory of Cardiovascular 
Science, NIA/NIH, Baltimore, MD, USA 192Department of Public Health and Primary 
Care, Leiden University Medical Center, Leiden, the Netherlands 
193Labormedizinisches Zentrum Dr. Risch, Schaan, Liechtenstein 194Private 
University of the Principality of Liechtenstin, Triesen, Liechtenstein 195University 
Insitute of Clinical Chemistry, Inselspital, Bern University Hospital, University of 
Bern, Bern, Switzerland 196Department of Cardiology, University of Groningen, 
University Medical Center Groningen, Groningen, The Netherlands 197Center for 
Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA 
198Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, 
USA 199Tennessee Valley Healthcare System (Nashville VA) & Vanderbilt University, 
TN, USA 200VA Boston Healthcare, Section of Cardiology and Department of 
Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 
USA 201Cardiovascular Health Research Unit, Departments of Medicine, 
Epidemiology and Health Services, University of Washington, Seattle, WA, USA 
202Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA 
203National Institute for Health Research Imperial Biomedical Research Centre, 
Imperial College Healthcare NHS Trust and Imperial College London, London, UK 
204UK Dementia Research Institute (UK DRI) at Imperial College London, London, 
UK 205Health Data Research-UK London substantive site, London, U.K.
Acknowledgements
H.R.W. was funded by the National Institute for Health Research (NIHR) as part of the portfolio of translational 
research of the NIHR Biomedical Research Centre at Barts and The London School of Medicine and Dentistry. 
D.M-A is supported by the Medical Research Council [grant number MR/L01632X.1]. B.M. holds an MRC 
eMedLab Medical Bioinformatics Career Development Fellowship, funded from award MR/L016311/1. H.G. was 
funded by the NIHR Imperial College Health Care NHS Trust and Imperial College London Biomedical Research 
Centre. C.P.C. was funded by the National Institute for Health Research (NIHR) as part of the portfolio of 
translational research of the NIHR Biomedical Research Center at Barts and The London School of Medicine and 
Dentistry. S.T. was supported by Canadian Institutes of Health Research; Université Laval (Quebec City, Canada). 
G.P. was supported by Canada Research Chair in Genetic and Molecular Epidemiology and CISCO Professorship 
in Integrated Health Biosystems. I.K. was supported by the EU PhenoMeNal project (Horizon 2020, 654241). 
C.P.K. is supported by grant U01DK102163 from the NIH-NIDDK, and by resources from the Memphis VA 
Medical Center. C.P.K. is an employee of the US Department of Veterans affairs. Opinions expressed in this paper 
are those of the authors’ and do not necessarily represent the opinion of the Department of Veterans Affairs. S.D. 
was supported for this work by grants from the European Research Council (ERC), the EU Joint Programme - 
Neurodegenerative Disease Research (JPND), the Agence Nationale de la Recherche (ANR). T.B., J.MART., V.V., 
A.F.W. and C.H. were supported by a core MRC grant to the MRCHGU QTL in Health and Disease research 
programme. M.BOE is supported by NIH grant R01-DK062370. H.W. and A.G. acknowledge support of the 
Tripartite Immunometabolism Consortium [TrIC], Novo Nordisk Foundation (grant NNF15CC0018486). N.V. was 
supported by Marie Sklodowska-Curie GF grant (661395) and ICIN-NHI. C.M. is funded by the MRC AimHy 
(MR/M016560/1) project grant. M.A.N participation is supported by a consulting contract between Data Tecnica 
International and the National Institute on Aging, NIH, Bethesda, MD, USA. M.BR., M.CO., I.G., P.G., G.G, 
Evangelou et al. Page 24
Nat Genet. Author manuscript; available in PMC 2018 December 07.
 E
urope PM
C
 Funders A
uthor M
anuscripts
 E
urope PM
C
 Funders A
uthor M
anuscripts
A.MO., A.R., D.V., C.M.B., C.F.S., M.T., D.T. were supported by the Italian Ministry of Health RF2010 to Paolo 
Gasparini, RC2008 to Paolo Gasparini. D.I.B. is supported by the Royal Netherlands Academy of Science Professor 
Award (PAH/6635). J.C.C. is supported by the Singapore Ministry of Health’s National Medical Research Council 
under its Singapore Translational Research Investigator (STaR) Award (NMRC/STaR/0028/2017). C.C., P.B.M and 
M.R.B were funded by the National Institutes for Health Research (NIHR) as part of the portfolio of translational 
research of the NIHR Biomedical Research Centre at Barts. T.F. is supported by the NIHR Biomedical Research 
Centre, Oxford. M.R. is recipient from China Scholarship Council (No. 2011632047). C.L. was supported by the 
Medical Research Council UK (G1000143; MC_UU_12015/1; MC_PC_13048; MC_U106179471), Cancer 
Research UK (C864/A14136), EU FP6 programme (LSHM_CT_2006_037197). G.B.E is supported by the Swiss 
National Foundation SPUM project FN 33CM30-124087, Geneva University, and the Fondation pour Recherches 
Médicales, Genève. C.M.L is supported by the Li Ka Shing Foundation, WT-SSI/John Fell funds and by the NIHR 
Biomedical Research Centre, Oxford, by Widenlife and NIH (CRR00070 CR00.01). R.J.F.L. is supported by the 
NIH (R01DK110113, U01HG007417, R01DK101855, R01DK107786). D.O.M-K. is supported by Dutch Science 
Organization (ZonMW-VENI Grant 916.14.023). M.M was supported by the National Institute for Health Research 
(NIHR) BioResource Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' 
NHS Foundation Trust and King's College London. H.W. and M.F. acknowledge the support of the Wellcome Trust 
core award (090532/Z/09/Z) and the BHF Centre of Research Excellence (RE/13/1/30181). A.G, H.W. 
acknowledge European Union Seventh Framework Programme FP7/2007-2013 under grant agreement no. 
HEALTH-F2-2013-601456 (CVGenes@Target) & and A.G, the Wellcome Trust Institutional strategic support fund. 
L.R. was supported by Forschungs- und Förder-Stiftung INOVA, Vaduz, Liechtenstein. M.TO. is supported by 
British Heart Foundation (PG/17/35/33001). P.S. is recipient of an NIHR Senior Investigator Award and is 
supported by the Biomedical Research Centre Award to Imperial College Healthcare NHS Trust. P.v.d.H. was 
supported by ICIN-NHI and Marie Sklodowska-Curie GF (call: H2020-MSCA-IF-2014, Project ID: 661395). 
N.J.W. was supported by the Medical Research Council UK (G1000143; MC_UU_12015/1; MC_PC_13048; 
MC_U106179471), Cancer Research UK (C864/A14136), EU FP6 programme (LSHM_CT_2006_037197). E.Z. 
was supported by the Wellcome Trust (WT098051). J.N.H. was supported by the Vanderbilt Molecular and Genetic 
Epidemiology of Cancer (MAGEC) training program, funded by T32CA160056 (PI: X.-O. Shu) and by VA grant 
1I01CX000982. A.G. was supported by VA grant 1I01CX000982. T.L.E. and D.R.V.E. were supported by grant 
R21HL121429 from NIH/NHLBI. A.M.H. was supported by VA Award #I01BX003360. C.J.O. was supported by 
the VA Boston Healthcare, Section of Cardiology and Department of Medicine, Brigham and Women’s Hospital, 
Harvard Medical School. The MRC/BHF Cardiovascular Epidemiology Unit is supported by the UK Medical 
Research Council [MR/L003120/1]; British Heart Foundation [RG/13/13/30194]; and UK National Institute for 
Health Research Cambridge Biomedical Research Centre. J.DA is a British Heart Foundation Professor and NIHR 
Senior Investigator. L.V.W. holds a GlaxoSmithKline/British Lung Foundation Chair in Respiratory Research. P.E. 
acknowledges support from the NIHR Biomedical Research Centre at Imperial College Healthcare NHS Trust and 
Imperial College London, the NIHR Health Protection Research Unit in Health Impact of Environmental Hazards 
(HPRU-2012-10141), and the Medical Research Council (MRC) and Public Health England (PHE) Centre for 
Environment and Health (MR/L01341X/1). P.E. is a UK Dementia Research Institute (DRI) professor, UK DRI at 
Imperial College London, funded by the MRC, Alzheimer’s Society and Alzheimer’s Research UK. He is also 
associate director of Health Data Research-UK London funded by a consortium led by the Medical Research 
Council. M.J.C. was funded by the National Institute for Health Research (NIHR) as part of the portfolio of 
translational research of the NIHR Biomedical Research Center at Barts and The London School of Medicine and 
Dentistry. M.J.C. is a National Institute for Health Research (NIHR) senior investigator and this work is funded by 
the MRC eMedLab award to M.J.C. and M.R.B. and the NIHR Biomedical Research Centre at Barts.
This research has been conducted using the UK Biobank Resource under Application Numbers 236 and 10035. 
This research was supported by the British Heart Foundation (grant SP/13/2/30111). Large-scale comprehensive 
genotyping of UK Biobank for cardiometabolic traits and diseases: UK CardioMetabolic Consortium (UKCMC).
Computing: This work was enabled using the computing resources of the i) UK MEDical BIOinformatics 
partnership - aggregation, integration, visualisation and analysis of large, complex data (UK MED-BIO) which is 
supported by the Medical Research Council [grant number MR/L01632X/1] and ii) the MRC eMedLab Medical 
Bioinformatics Infrastructure, supported by the Medical Research Council [grant number MR/L016311/1].
URLs
FORGE: http://browser.1000genomes.org/Homo_sapiens/UserData/Forge?db=core
Fantom5 data: http://fantom.gsc.riken.jp/5/
ENCODE DNase I data: (wgEncodeAwgDnaseMasterSites; accessed using Table browser)
ENCODE cell type data: http://genome.ucsc.edu/ENCODE/cellTypes.html.
Evangelou et al. Page 25
Nat Genet. Author manuscript; available in PMC 2018 December 07.
 E
urope PM
C
 Funders A
uthor M
anuscripts
 E
urope PM
C
 Funders A
uthor M
anuscripts
GTEx: www.gtexportal.org
DeepSEA: http://deepsea.princeton.edu/
WebGestalt: http://www.webgestalt.org
IPA: www.qiagen.com/ingenuity
Mouse Genome Informatics (MGI): http://www.informatics.jax.org/batch
Drug Gene Interaction database: www.dgidb.org
PhenoScanner: http://www.phenoscanner.medschl.cam.ac.uk (Phenoscanner integrates 
results from the GWAS catalogue: https://www.ebi.ac.uk/gwas/ and GRASP: https://
grasp.nhlbi.nih.gov/)
DisGeNEt: http://www.disgenet.org
GeneATLAS: http//geneatlas.roslin.ed.ac.uk
Global Biobank Engine: https://biobankengine.stanford.edu
Data availability statement
The UKB GWAS data can be assessed from the UK Biobank data repository (http://
biota.osc.ox.ac.uk/). The genetic and phenotypic UKB data are available upon application to 
the UK Biobank (https://www.ukbiobank.ac.uk). ICBP summary data can be assessed 
through request to ICBP steering committee. Contact Mark Caulfield 
(m.j.caulfield@qmul.ac.uk) or Paul Elliott (p.elliott@imperial.ac.uk) to apply for access to 
the data. The UKB+ICBP summary data can be assessed through request to Paul Elliott 
(p.elliott@imperial.ac.uk) or Mark Caulfield (m.j.caulfield@qmul.ac.uk). All replication 
data generated during this study are included in the published article. For example, 
association results of look-up variants from our replication analyses and the subsequent 
combined meta-analyses are contained within the Supplementary Tables provided.
Ethics Statement
The UKB study has approval from the North West Multi-Centre Research Ethics Committee. 
Any participants from UKB who withdrew consent have been removed from our analysis. 
Each cohort within the ICBP meta-analysis as well as our independent replication cohorts of 
MVP and EGCUT had ethical approval locally. More information on the participating 
cohorts is available in Supplementary Methods.
Conflicts/Disclosures
K.W. is a Commercial partnerships manager for Genomics England, a UK Government 
Company
Evangelou et al. Page 26
Nat Genet. Author manuscript; available in PMC 2018 December 07.
 E
urope PM
C
 Funders A
uthor M
anuscripts
 E
urope PM
C
 Funders A
uthor M
anuscripts
M.A.N. consults for Illumina Inc, the Michael J. Fox Foundation and University of 
California Healthcare among others.
A.S.B. has received grants outside of this work from Merck, Pfizer, Novartis, AstraZeneca, 
Biogen and Bioverativ and personal fees from Novartis
J.DA. has the following competing interests: Pfizer Population Research Advisory Panel 
(grant), AstraZeneca (grant), Wellcome Trust (grant), UK Medical Research Council (grant), 
Pfizer(grant), Novartis (grant), NHS Blood and Transplant(grant), National Institute of 
Health Research(grant), UK MEDICAL RESEARCH COUNCIL(grant), BRITISH HEART 
FOUNDATION(grant),UK NATIONAL INSTITUTE OF HEALTH RESEARCH (grant), 
EUROPEAN COMMISSION (grant), Merck Sharp and Dohme UK Atherosclerosis 
(personal fees), Novartis Cardiovascular and Metabolic Advisory Board (personal fees), 
British Heart Foundation (grant), European Research Council (grant), Merck (grant).
B.M.P. serves on the DSMB of a clinical trial funded by Zoll LifeCor and on the Steering 
Committee of the Yale Open Data Access Project funded by Johnson & Johnson.
M.J.C. is Chief Scientist for Genomics England, a UK Government company.
The views expressed in this manuscript are those of the authors and do not necessarily 
represent the views of the National Heart, Lung, and Blood Institute; the National Institutes 
of Health; or the U. S. Department of Health and Human Services. This publication does not 
represent the views of the Department of Veterans Affairs or the United States Government.
References
1. Forouzanfar MH, et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 
to 115 mm Hg, 1990-2015. JAMA. 2017; 317:165–182. [PubMed: 28097354] 
2. Munoz M, et al. Evaluating the contribution of genetics and familial shared environment to common 
disease using the UK Biobank. Nat Genet. 2016; 48:980–3. [PubMed: 27428752] 
3. Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet. 2015; 386:801–12. [PubMed: 
25832858] 
4. Feinleib M, et al. The NHLBI twin study of cardiovascular disease risk factors: methodology and 
summary of results. Am J Epidemiol. 1977; 106:284–5. [PubMed: 562066] 
5. Cabrera CP, et al. Exploring hypertension genome-wide association studies findings and impact on 
pathophysiology, pathways, and pharmacogenetics. Wiley Interdiscip Rev Syst Biol Med. 2015; 
7:73–90. [PubMed: 25655479] 
6. Ehret GB, et al. The genetics of blood pressure regulation and its target organs from association 
studies in 342,415 individuals. Nat Genet. 2016; 48:1171–1184. [PubMed: 27618452] 
7. Surendran P, et al. Trans-ancestry meta-analyses identify rare and common variants associated with 
blood pressure and hypertension. Nat Genet. 2016; 48:1151–1161. [PubMed: 27618447] 
8. Liu C, et al. Meta-analysis identifies common and rare variants influencing blood pressure and 
overlapping with metabolic trait loci. Nat Genet. 2016; 48:1162–70. [PubMed: 27618448] 
9. Hoffmann TJ, et al. Genome-wide association analyses using electronic health records identify new 
loci influencing blood pressure variation. Nat Genet. 2017; 49:54–64. [PubMed: 27841878] 
10. Warren HR, et al. Genome-wide association analysis identifies novel blood pressure loci and offers 
biological insights into cardiovascular risk. Nat Genet. 2017; 49:403–415. [PubMed: 28135244] 
11. Wain LV, et al. Novel Blood Pressure Locus and Gene Discovery Using Genome-Wide Association 
Study and Expression Data Sets From Blood and the Kidney. Hypertension. 2017
Evangelou et al. Page 27
Nat Genet. Author manuscript; available in PMC 2018 December 07.
 E
urope PM
C
 Funders A
uthor M
anuscripts
 E
urope PM
C
 Funders A
uthor M
anuscripts
12. International Consortium for Blood Pressure Genome-Wide Association Studies. et al. Genetic 
variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011; 
478:103–9. [PubMed: 21909115] 
13. Sudlow C, et al. UK biobank: an open access resource for identifying the causes of a wide range of 
complex diseases of middle and old age. PLoS Med. 2015; 12:e1001779. [PubMed: 25826379] 
14. Gaziano JM, et al. Million Veteran Program: A mega-biobank to study genetic influences on health 
and disease. J Clin Epidemiol. 2016; 70:214–23. [PubMed: 26441289] 
15. Leitsalu L, et al. Cohort Profile: Estonian Biobank of the Estonian Genome Center, University of 
Tartu. Int J Epidemiol. 2015; 44:1137–47. [PubMed: 24518929] 
16. McCarthy S, et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet. 
2016; 48:1279–83. [PubMed: 27548312] 
17. Loh PR, et al. Efficient Bayesian mixed-model analysis increases association power in large 
cohorts. Nat Genet. 2015; 47:284–90. [PubMed: 25642633] 
18. Bulik-Sullivan BK, et al. LD Score regression distinguishes confounding from polygenicity in 
genome-wide association studies. Nat Genet. 2015; 47:291–5. [PubMed: 25642630] 
19. Ioannidis JP, Patsopoulos NA, Evangelou E. Heterogeneity in meta-analyses of genome-wide 
association investigations. PLoS One. 2007; 2:e841. [PubMed: 17786212] 
20. Evangelou E, Ioannidis JP. Meta-analysis methods for genome-wide association studies and 
beyond. Nat Rev Genet. 2013; 14:379–89. [PubMed: 23657481] 
21. Pulit SL, de With SA, de Bakker PI. Resetting the bar: Statistical significance in whole-genome 
sequencing-based association studies of global populations. Genet Epidemiol. 2017; 41:145–151. 
[PubMed: 27990689] 
22. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait 
analysis. Am J Hum Genet. 2011; 88:76–82. [PubMed: 21167468] 
23. Rao SS, et al. A 3D map of the human genome at kilobase resolution reveals principles of 
chromatin looping. Cell. 2014; 159:1665–80. [PubMed: 25497547] 
24. Schmitt AD, et al. A Compendium of Chromatin Contact Maps Reveals Spatially Active Regions 
in the Human Genome. Cell Rep. 2016; 17:2042–2059. [PubMed: 27851967] 
25. Dunham IKE, Iotchkova V, Morganella S, Birney E. FORGE: A tool to discover cell specific 
enrichments of GWAS associated SNPs in regulatory regions. F1000Research. 2015; 4
26. MacArthur J, et al. The new NHGRI-EBI Catalog of published genome-wide association studies 
(GWAS Catalog). Nucleic Acids Res. 2017; 45:D896–D901. [PubMed: 27899670] 
27. Staley JR, et al. PhenoScanner: a database of human genotype-phenotype associations. 
Bioinformatics. 2016; 32:3207–3209. [PubMed: 27318201] 
28. Pinero J, et al. DisGeNET: a discovery platform for the dynamical exploration of human diseases 
and their genes. Database (Oxford). 2015; 2015 bav028. 
29. Pinero J, et al. DisGeNET: a comprehensive platform integrating information on human disease-
associated genes and variants. Nucleic Acids Res. 2017; 45:D833–D839. [PubMed: 27924018] 
30. Elliott P, et al. The Airwave Health Monitoring Study of police officers and staff in Great Britain: 
rationale, design and methods. Environ Res. 2014; 134:280–5. [PubMed: 25194498] 
31. Ehret GB, Caulfield MJ. Genes for blood pressure: an opportunity to understand hypertension. Eur 
Heart J. 2013; 34:951–61. [PubMed: 23303660] 
32. Blood Pressure Lowering Treatment Trialists C. et al. Blood pressure-lowering treatment based on 
cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014; 384:591–8. [PubMed: 
25131978] 
33. GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment 
of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 
1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 
388:1659–1724. [PubMed: 27733284] 
34. Nakao E, et al. Elevated Plasma Transforming Growth Factor beta1 Levels Predict the 
Development of Hypertension in Normotensives: The 14-Year Follow-Up Study. Am J Hypertens. 
2017; 30:808–814. [PubMed: 28575138] 
Evangelou et al. Page 28
Nat Genet. Author manuscript; available in PMC 2018 December 07.
 E
urope PM
C
 Funders A
uthor M
anuscripts
 E
urope PM
C
 Funders A
uthor M
anuscripts
35. Feng W, Dell'Italia LJ, Sanders PW. Novel Paradigms of Salt and Hypertension. J Am Soc 
Nephrol. 2017; 28:1362–1369. [PubMed: 28220030] 
36. International PPH Consortium. et al. Heterozygous germline mutations in BMPR2, encoding a 
TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet. 2000; 26:81–4. 
[PubMed: 10973254] 
37. Voight BF, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale 
association analysis. Nat Genet. 2010; 42:579–89. [PubMed: 20581827] 
38. Douma S, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective 
observational study. Lancet. 2008; 371:1921–6. [PubMed: 18539224] 
39. Rossi GP, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 
hypertensive patients. J Am Coll Cardiol. 2006; 48:2293–300. [PubMed: 17161262] 
40. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among 
black and white subjects with resistant hypertension. Hypertension. 2002; 40:892–6. [PubMed: 
12468575] 
41. Drelon C, Berthon A, Mathieu M, Martinez A, Val P. Adrenal cortex tissue homeostasis and 
zonation: A WNT perspective. Mol Cell Endocrinol. 2015; 408:156–64. [PubMed: 25542843] 
42. El Wakil A, Lalli E. The Wnt/beta-catenin pathway in adrenocortical development and cancer. Mol 
Cell Endocrinol. 2011; 332:32–7. [PubMed: 21094679] 
43. Teo AE, et al. Pregnancy, Primary Aldosteronism, and Adrenal CTNNB1 Mutations. N Engl J 
Med. 2015; 373:1429–36. [PubMed: 26397949] 
44. Tissier F, et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling 
pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 
2005; 65:7622–7. [PubMed: 16140927] 
45. Oliveira-Paula GH, et al. Polymorphisms in VEGFA gene affect the antihypertensive responses to 
enalapril. Eur J Clin Pharmacol. 2015; 71:949–57. [PubMed: 26002049] 
46. Yang R, et al. Hypertension and endothelial dysfunction in apolipoprotein E knockout mice. 
Arterioscler Thromb Vasc Biol. 1999; 19:2762–8. [PubMed: 10559023] 
47. Sofat R, et al. Circulating Apolipoprotein E Concentration and Cardiovascular Disease Risk: Meta-
analysis of Results from Three Studies. PLoS Med. 2016; 13:e1002146. [PubMed: 27755538] 
48. Conrad KP. Unveiling the vasodilatory actions and mechanisms of relaxin. Hypertension. 2010; 
56:2–9. [PubMed: 20497994] 
49. Sun HJ, et al. Relaxin in paraventricular nucleus contributes to sympathetic overdrive and 
hypertension via PI3K-Akt pathway. Neuropharmacology. 2016; 103:247–56. [PubMed: 
26746861] 
50. Miyamoto Y, et al. Phosphatidylinositol 3-kinase inhibition induces vasodilator effect of 
sevoflurane via reduction of Rho kinase activity. Life Sci. 2017; 177:20–26. [PubMed: 28400117] 
51. Pawlak JB, Wetzel-Strong SE, Dunn MK, Caron KM. Cardiovascular effects of exogenous 
adrenomedullin and CGRP in Ramp and Calcrl deficient mice. Peptides. 2017; 88:1–7. [PubMed: 
27940069] 
52. Ohtsu H, et al. Signal-crosstalk between Rho/ROCK and c-Jun NH2-terminal kinase mediates 
migration of vascular smooth muscle cells stimulated by angiotensin II. Arterioscler Thromb Vasc 
Biol. 2005; 25:1831–6. [PubMed: 15994438] 
53. Tzoulaki I, Elliott P, Kontis V, Ezzati M. Worldwide Exposures to Cardiovascular Risk Factors and 
Associated Health Effects: Current Knowledge and Data Gaps. Circulation. 2016; 133:2314–33. 
[PubMed: 27267538] 
54. Munafo MR, Tilling K, Taylor AE, Evans DM, Davey Smith G. Collider scope: when selection 
bias can substantially influence observed associations. Int J Epidemiol. 2017; 47:226–235.
55. Pazoki R, et al. Genetic predisposition to high blood pressure and lifestyle factors: Associations 
with midlife blood pressure levels and cardiovascular events. Circulation. 2018; 137:653–661. 
[PubMed: 29254930] 
56. Boyle EA, Li YI, Pritchard JK. An expanded view of complex traits. From polygenic to omnigenic. 
Cell. 2017; 169:1177–1186. [PubMed: 28622505] 
Evangelou et al. Page 29
Nat Genet. Author manuscript; available in PMC 2018 December 07.
 E
urope PM
C
 Funders A
uthor M
anuscripts
 E
urope PM
C
 Funders A
uthor M
anuscripts
57. Wain LV, et al. Novel insights into the genetics of smoking behaviour, lung function, and chronic 
obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank. Lancet 
Respir Med. 2015; 3:769–81. [PubMed: 26423011] 
58. Bycroft CFC, Petkova D, Band G, Elliot LT, Sharp K, Motyer A, Vukcevic D, Delaneau O, 
O'Conell J, Cortes A, Welsh S, et al. Genome-wide geentic data on 500,000 UK Biobank 
Participants. bioRxiv. 2017 166298. 
59. Tobin MD, Sheehan NA, Scurrah KJ, Burton PR. Adjusting for treatment effects in studies of 
quantitative traits: antihypertensive therapy and systolic blood pressure. Stat Med. 2005; 24:2911–
35. [PubMed: 16152135] 
60. Marouli E, et al. Rare and low-frequency coding variants alter human adult height. Nature. 2017; 
542:186–190. [PubMed: 28146470] 
61. Wain LV, et al. Genome-wide association study identifies six new loci influencing pulse pressure 
and mean arterial pressure. Nat Genet. 2011; 43:1005–11. [PubMed: 21909110] 
62. 1000 Genomes Project Consortium. et al. A global reference for human genetic variation. Nature. 
2015; 526:68–74. [PubMed: 26432245] 
63. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association 
scans. Bioinformatics. 2010; 26:2190–1. [PubMed: 20616382] 
64. Purcell S, et al. PLINK: a tool set for whole-genome association and population-based linkage 
analyses. Am J Hum Genet. 2007; 81:559–75. [PubMed: 17701901] 
65. Zhou J, Troyanskaya OG. Predicting effects of noncoding variants with deep learning-based 
sequence model. Nat Methods. 2015; 12:931–4. [PubMed: 26301843] 
66. Pers TH, et al. Biological interpretation of genome-wide association studies using predicted gene 
functions. Nat Commun. 2015; 6 5890. 
67. Wang J, Vasaikar S, Shi Z, Greer M, Zhang B. WebGestalt 2017: a more comprehensive, powerful, 
flexible and interactive gene set enrichment analysis toolkit. Nucleic Acids Res. 2017
68. Canela-Xandri O, Konrad R, Tenesa Albert. An atlas of genetic associations in UK Biobank. 
bioRxiv. 2017 176834. 
Evangelou et al. Page 30
Nat Genet. Author manuscript; available in PMC 2018 December 07.
 E
urope PM
C
 Funders A
uthor M
anuscripts
 E
urope PM
C
 Funders A
uthor M
anuscripts
Figure 1. 
Study design schematic for discovery and validation of loci. ICBP; International 
Consortium for Blood Pressure; N, sample size; QC, quality control; PCA, principal-
component analysis; GWAS, Genome-wide Association Study; 1000G 1000 Genomes; 
HRC, Haplotype Reference Panel; BP: blood pressure; SNPs, single nucleotide 
polymorphisms; BMI, body mass index; LMM; linear mixed model; UKB, UK Biobank, 
MAF, minor allele frequency; HLA, Human Leukocyte Antigen; MVP, Million Veterans 
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Program; EGCUT; Estonian Genome Center, University of Tartu; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; PP, pulse pressure.
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Figure 2. 
Manhattan plot showing the minimum P-value for the association across all blood 
pressure traits in the discovery stage excluding known and previously reported 
variants. Manhattan plot of the discovery genome-wide association meta-analysis in 
757,601 individuals excluding variants in 274 known loci. The minimum P-value, computed 
using inverse variance fixed effects meta-analysis, across SBP, DBP and PP is presented. 
The y axis shows the –log10 P values and the x axis shows their chromosomal positions. 
Horizontal red and blue line represents the thresholds of P = 5 x 10-8 for genome-wide 
significance and P = 1 x 10-6 for selecting SNPs for replication, respectively. SNPs in blue 
are in LD (r2 > 0.8) with the 325 novel variants independently replicated from the 2-stage 
design whereas SNPs in red are in LD (r2 > 0.8) with 210 SNPs identified through the 1-
stage design with internal replication. Any loci in black or grey that exceed the significance 
thresholds were significant in the discovery meta-analysis, but did not meet the criteria of 
replication in the one- or two-stage designs.
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Figure 3. 
Venn Diagrams of Novel Loci Results (a) “Comparison of 1-stage and 2-stage design 
analysis criteria”: For all 535 novel loci, we compare the results according to the 
association criteria used for the one-stage and the two-stage design. Two-hundred and ten 
loci exclusively met the one-stage analysis criteria (P <5x10-9 in the discovery meta-analysis 
[N=757,601], P < 0.01 in UKB [N=458,577], P < 0.01 in ICBP [N=299,024] and concordant 
direction of effect between UKB and ICBP). The P-values for the discovery and the ICBP 
meta-analyses were calculated using inverse variance fixed effects meta-analysis. The P-
values in UKB were derived from linear mixed modeling using BOLT-LMM. Of the 325 
novel replicated loci from the 2-stage analysis (genome-wide significance in the combined 
meta-analysis, P < 0.01 in the replication meta-analysis and concordant direction of effect), 
204 loci would also have met the one-stage criteria, whereas 121 were only identified by the 
two-stage analysis. (b) “Overlap of Associations across Blood Pressure Traits”. For all 
535 novel loci, we show the number of loci associated with each blood pressure trait. We 
present the two-stage loci first, followed by the one-stage loci. SBP: systolic blood pressure; 
DBP: diastolic blood pressure; PP: pulse pressure; UKB: UK Biobank; ICBP: International 
Consortium of Blood Pressure.
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Figure 4. 
Association of blood pressure loci with lifestyle traits. Plot shows unsupervised 
hierarchical clustering of BP loci based on associations with lifestyle-related factors. For the 
sentinel SNP at each BP locus (x-axis), we calculated the -log10(P)*sign(β) (aligned to BP-
raising allele) as retrieved from the Gene Atlas catalogue (http://geneatlas.roslin.ed.ac.uk). 
The P-values in Gene Atlas were calculated applying linear mixed models. BP loci and traits 
were clustered according to the Euclidean distance amongst -log10(P)*sign(β). Red squares 
indicate direct associations with the trait of interest and blue squares inverse associations. 
Only SNPs with at least one association at P <10-6 with at least one of the traits examined 
are annotated in the heat-map. All 901 loci are considered, both known and novel: novel loci 
are printed in bold font. SNPs: Single Nucleotide Polymorphisms; BP: Blood Pressure.
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Figure 5. 
Association of blood pressure loci with other traits. Plot shows results from associations 
with other traits which were extracted from the GWAS catalog and PhenoScanner databases 
for the 535 novel sentinel SNPs including proxies in Linkage Disequilibrium (r2 ≥ 0.8) with 
genome-wide significant associations. SBP: Systolic Blood Pressure; DBP: Diastolic Blood 
Pressure; PP: Pulse Pressure; HR: Heart Rate; ECG: Electrocardiographic traits; CAD: 
Coronary Artery Disease CHD; Coronary Heart Disease MI; Myocardial Infraction; T2D: 
Type II Diabetes.
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Figure 6. 
Association of blood pressure loci with other traits. Plots (a) and (b) show overlap 
between variants associated to (a) traits and (b) diseases in the manually-curated version of 
the DisGeNET database, and all variants in LD r2>0.8 with the known (red bars) SNPs from 
the 274 published loci, and all (green bars) BP variants from all 901 loci. Numbers on top of 
the bars denote the number of SNPs included in DisGeNET for the specific trait or disease. 
Traits/diseases with an overlap of at least 5 variants in LD with all markers are shown. The 
Y axis shows the percentage of variants associated with the diseases that is covered by the 
overlap. For the sake of clarity, the DisGeNET terms for blood pressure and hypertension are 
not displayed, whereas the following diseases have been combined: coronary artery disease 
(CAD), coronary heart disease (CHD) and myocardial infarction (MI); prostate and breast 
carcinoma; Crohn's and inflammatory bowel diseases.
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Figure 7. 
Relationship of deciles of the genetic risk score (GRS) based on all 901 loci with blood 
pressure, risk of hypertension and cardiovascular disease in UK Biobank. The plots 
show sex-adjusted (a) mean systolic blood pressure (SBP) and odds ratios of hypertension 
(HTN) (N=364,520) and (b) odds ratios of incident cardiovascular disease (CVD), 
myocardial infarction (MI) and stroke (N=392,092), comparing each of the upper nine GRS 
deciles with the lowest decile; dotted lines represent the upper 95% confidence intervals.
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Figure 8. 
Known and novel BP associations in the TGFβ signalling pathway. Genes with known 
associations with BP are indicated in cyan. Genes with novel associations with BP reported 
in this study are indicated in red. TGFβ pathway was derived from an ingenuity canonical 
pathway. BP: Blood Pressure.
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